BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
WITH INDEPENDENT AUDITORS' REVIEW REPORT
FOR THE SIX MONTHS ENDED
JUNE 30, 2025 AND 2024

Address: 6F., No. 2, Aly. 36, Ln. 26, Ruiguang Rd., Neihu Dist., Taipei City, Taiwan (R.O.C.)
Telephone：886-2-2790-1555

The reader is advised that these financial statements have been prepared originally in Chinese. In the event of a conflict between these financial statements and the original Chinese version or difference in interpretation between the two versions, the Chinese language financial statements shall prevail.

安永聯合會計師事務所

70051 台南市永福路一段189號11樓
11F, No.189, Sec. 1, Yongfu Road
Tainan City, Taiwan, R.O.C

Tel: 886 6 292 5888
Fax: 886 6 200 6888
www.ey.com/taiwan

Independent Auditors' Review Report

To the Board of Directors and Shareholders
Bora Pharmaceuticals Co., Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of Bora Pharmaceuticals Co., Ltd. (the "Company") and its subsidiaries (collectively, the "Group") as of June 30, 2025 and 2024, and the related consolidated statements of comprehensive income for the three months ended June 30, 2025 and 2024 and for the six months ended June 30, 2025 and 2024, the consolidated statements of changes in equity and cash flows for the six months ended June 30, 2025 and 2024, and notes to the consolidated financial statements, including the summary of significant accounting policies (collectively referred to as the "consolidated financial statements"). Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standards 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagement of the Republic of China 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity". A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews and the audit reports of other independent auditors (please refer to the Other Matter paragraph of our report), nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Company as of June 30, 2025 and 2024, its consolidated financial performance for the three months ended June 30, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the six months ended June 30, 2025 and 2024 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standards 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

EY 安永
Building a better working world

Other Matter－Making Reference to the Audit of Other Independent Auditors

We did not audit the financial statements of certain associates and joint ventures accounted for under the equity method. Our review, insofar as it relates to investments accounted for using equity method balances of NT$4,668,555 thousands, which represented 11% of consolidated total assets as of June 30, 2025, the related shares of (loss) from the associates and joint ventures accounted for using the equity method in the amount of NT$(103,731) thousands and NT$(222,199) thousands, which represented (22)% and (10)% of the consolidated net income before income tax for the three months and the six months ended June 30, 2025, respectively, and the related shares of other comprehensive income (loss) from the associates and joint ventures in the amount of NT$(103,147) thousands and NT$(90,739) thousands, which represented 6% and 6% of the consolidated total comprehensive income (loss) for the three months and the six months ended June 30, 2025, respectively, are based on Soley on the reports of other independent auditors.

Hu, Tzu Ren

Yao, Shih Chieh

Ernst & Young, Taiwan

August 8, 2025

Notice to Readers
The accompanying consolidated financial statements are intended only to present the consolidated financial position, results of operations and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

Accordingly, the accompanying consolidated financial statements and report of independent auditors are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice. As the consolidated financial statements are the responsibility of the management, Ernst & Young cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

English Translation of Consolidated Financial Statements Originally Issued in Chinese

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

Unit: Thousands of New Taiwan Dollars

ASSETS	Notes	June 30, 2025		December 31, 2024		June 30, 2024	
		Amount	%	Amount	%	Amount	%
Current assets							
Cash and cash equivalents	IV&VI.1	$4,309,662	10	$5,829,197	13	$5,509,578	13
Financial assets measured at fair value through profit or loss, current	IV&VI.2	30,597	-	24,477	-	21,635	-
Financial assets at amortized cost, current	IV&VI.4&VIII	35,827	-	67,862	-	2,051,809	5
Contract assets, current	IV&VI.23	446,482	1	239,991	-	168,893	-
Notes receivable, net	IV&VI.5.24	8,228	-	19,884	-	32,443	-
Accounts receivable, net	IV&VI.6.24&VII	7,644,976	18	10,221,933	22	9,551,188	22
Other receivables	IV&VII	361,238	1	772,039	2	735,990	2
Inventories, net	IV&VI.7	3,225,010	8	5,502,342	12	4,985,248	12
Prepayments		554,218	2	591,004	2	996,428	2
Disposal groups classified as held for sale, net	IV&VI.8	1,008,598	2	-	-	-	-
Other current assets		158,396	-	114,427	-	128,049	-
Total current assets		17,783,232	42	23,383,156	51	24,181,261	56
Non-current assets							
Financial assets measured at fair value through profit or loss, non-current	IV&VI.2	93,015	-	99,165	-	91,249	-
Financial assets measured at fair value through other comprehensive income, non-current	IV&VI.3	198,494	-	221,456	-	208,258	-
Financial assets measured at amortized cost, non-current	IV&VI.4&VIII	13,200	-	13,500	-	13,500	-
Investments accounted for using equity method	IV&VI.9	4,669,939	11	1,370	-	1,077	-
Property, plant and equipment	IV&VI.10&VIII	9,928,326	24	11,684,248	26	10,261,449	24
Right-of-use assets	IV&VI.25	794,441	2	825,505	2	843,407	2
Investment properties, net	IV&VI.11&VIII	11,965	-	16,410	-	16,714	-
Intangible assets	IV&VI.12.13	6,207,942	15	7,533,165	17	6,026,357	14
Deferred tax assets	IV&VI.29	1,641,406	4	1,190,246	3	1,095,271	3
Other non-current assets		622,002	2	542,041	1	608,648	1
Total non-current assets		24,180,730	58	22,127,106	49	19,165,930	44
Total assets		$41,963,962	100	$45,510,262	100	$43,347,191	100

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translation of Consolidated Financial Statements Originally Issued in Chinese

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

Unit: Thousands of New Taiwan Dollars

LIABILITIES AND EQUITY	Notes	June 30, 2025		December 31, 2024		June 30, 2024	
		Amount	%	Amount	%	Amount	%
Current liabilities							
Short-term loans	IV&VI.14	$1,933,560	5	$2,597,850	6	$7,776,718	18
Financial liabilities measured at fair value through profit or loss, current	IV&VI.15	450,976	1	806,650	2	324,792	1
Contract liabilities, current	IV&VI.23	238,584	1	245,598	-	266,629	1
Notes payable		2,605	-	5,861	-	15,891	-
Accounts payable		852,643	2	786,480	2	766,223	2
Other payables	VII	2,323,150	6	3,276,666	7	3,304,665	7
Dividends payable		1,500,491	4	-	-	1,215,057	3
Income tax payable	IV&VI.29	363,616	1	484,332	1	452,754	1
Provisions, current	IV&VI.19	160,342	-	248,120	-	259,973	1
Liabilities related to disposal groups classified as held for sale	IV&VI.8	87,846	-	-	-	-	-
Lease liabilities, current	IV&VI.25	90,088	-	116,600	-	109,070	-
Current portion of long-term loans	VI.17	1,622,141	4	1,189,023	3	1,277,303	3
Refund liabilities	IV&VI.23	2,595,195	6	3,908,335	9	4,585,789	10
Other current liabilities	VI.20	52,177	-	143,082	-	47,671	-
Total current liabilities		12,273,414	30	13,808,597	30	20,402,535	47
Non-current liabilities							
Financial liabilities measured at fair value through profit or loss, non-current	IV&VI.15	227,708	1	257,263	1	-	-
Contract liabilities, non-current	IV&VI.23	26,071	-	-	-	-	-
Bonds payable	IV&VI.16	7,751,500	18	7,758,905	17	1,555,114	4
Long-term loans	VI.17	5,618,127	13	6,564,987	14	7,126,916	16
Provisions, non-current	IV&VI.19	96,788	-	129,036	-	184,731	-
Deferred tax liabilities	IV&VI.29	1,132,405	3	1,255,861	3	882,000	2
Lease liabilities, non-current	IV&VI.25	739,653	2	745,962	2	765,309	2
Other non-current liabilities	VI.20	30,137	-	66,322	-	134,204	-
Total non-current liabilities		15,622,389	37	16,778,336	37	10,648,274	24
Total liabilities		27,895,803	67	30,586,933	67	31,050,809	71
Equity attributable to the parent company	VI.21						
Capital							
Common stock		1,037,174	2	1,030,852	2	1,015,501	2
Advance receipts for ordinary share		478	-	2,267	-	92	-
Stock dividends to be distributed		206,828	1	-	-	-	-
Capital surplus		4,579,315	11	4,408,236	10	3,384,992	8
Retained earnings							
Legal reserve		1,019,626	2	658,515	1	658,515	1
Unappropriated earnings		6,360,992	15	6,361,911	14	4,656,762	11
Subtotal		7,380,618	17	7,020,426	15	5,315,277	12
Other equity		(1,143,326)	(3)	360,566	1	211,372	1
Treasury stock		(64,646)	-	(43,181)	-	(438,856)	(1)
Equity attributable to shareholders of the parent		11,996,441	28	12,779,166	28	9,488,378	22
Non-controlling interests	VI.21	2,071,718	5	2,144,163	5	2,808,004	7
Total equity		14,068,159	33	14,923,329	33	12,296,382	29
Total liabilities and equity		$41,963,962	100	$45,510,262	100	$43,347,191	100

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translation of Consolidated Financial Statements Originally Issued in Chinese

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEEMENTS OF COMPREHENSIVE INCOME

Unit: Thousands of New Taiwan Dollars

Items	Notes	For the three months ended June 30, 2025		For the three months ended June 30, 2024		For the six months ended June 30, 2025		For the six months ended June 30, 2024	
		Amount	%	Amount	%	Amount	%	Amount	%
Operating revenue	IV&VI.23&VII	$4,867,785	100	$4,417,206	100	$9,347,370	100	$7,274,699	100
Operating costs	VI.7.10.11.18.25.26&VII	(2,848,402)	(59)	(2,449,985)	(55)	(5,438,490)	(58)	(3,801,488)	(52)
Gross profit		2,019,383	41	1,967,221	45	3,908,880	42	3,473,211	48
Unrealized (profis) on sales		(149)	-	(73)	-	(200)	-	(73)	-
Realized profit on from sale		43	-	-	-	83	-	-	-
Net gross profit		2,019,277	41	1,967,148	45	3,908,763	42	3,473,138	48
Operating expenses	VI.10.11.18.22.24.25.26&VII								
Sales and marketing expenses		(296,717)	(6)	(256,205)	(6)	(671,156)	(7)	(456,713)	(6)
General and administrative expenses		(573,941)	(12)	(640,723)	(15)	(1,219,714)	(13)	(960,635)	(13)
Research and development expenses		(155,967)	(3)	(164,193)	(4)	(343,869)	(4)	(257,720)	(4)
Total operating expenses		(1,026,625)	(21)	(1,061,121)	(25)	(2,234,739)	(24)	(1,675,068)	(23)
Operating income		992,652	20	906,027	20	1,674,024	18	1,798,070	25
Non-operating income and expenses	VI.27								
Other revenue		42,917	1	32,394	1	58,931	1	39,547	1
Other gains and (losses)		(259,826)	(5)	99,133	2	2,299,325	25	215,727	3
Financial costs		(116,718)	(3)	(142,194)	(3)	(237,499)	(3)	(174,444)	(3)
Share of (loss) of associates and joint ventures accounted for using the equity method		(103,630)	(2)	(165)	-	(221,986)	(3)	(165)	-
Bargain purchase gain		-	-	712,211	16	-	-	712,211	10
Total non-operating income and (expenses)		(437,257)	(9)	701,379	16	1,898,771	20	792,876	11
Net income before income tax		555,395	11	1,607,406	36	3,572,795	38	2,590,946	36
Income tax expense	IV&VI.29	(107,523)	(2)	(298,188)	(7)	(374,215)	(4)	(538,067)	(7)
Net income from continuing operations		447,872	9	1,309,218	29	3,198,580	34	2,052,879	29
Total income (loss) from discontinued operations		187,257	4	(182,089)	(4)	(1,154,666)	(12)	(182,089)	(3)
Net income		635,129	13	1,127,129	25	2,043,914	22	1,870,790	26
Other comprehensive income	IV&VI.28.29								
Components of other comprehensive income that will not be reclassified to profit or loss									
Unrealized gains or (losses) from equity instruments investments measured at fair value through other comprehensive income		(11,902)	-	18,958	-	(5,612)	-	18,958	-
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss		2,134	-	(3,792)	-	876	-	(3,792)	-
To be reclassified to profit or (loss) in subsequent periods									
Exchange differences resulting from translation foreign operations		(2,121,108)	(44)	72,916	2	(1,875,114)	(20)	153,041	2
Income tax related to items to be reclassified subsequently to profit or loss		424,138	9	(14,590)	-	374,958	4	(30,593)	-
Total other comprehensive income, net of tax		(1,706,738)	(35)	73,492	2	(1,504,892)	(16)	137,614	2
Total comprehensive income		$(1,071,609)	(22)	$1,200,621	27	$539,022	6	$2,008,404	28
Net income attributable to:									
Stockholders of the parent		$616,669		$1,085,321		$2,015,942		$1,801,458	
Non-controlling interests		$18,460		$41,808		$27,972		$69,332	
Comprehensive income attributable to:									
Stockholders of the parent		$(1,089,010)		$1,158,834		$512,050		$1,939,023	
Non-controlling interests		$17,401		$41,787		$26,972		$69,381	
Earnings per share (NTD)	IV&VI.30								
Profit from continuing operations		$4.14		$12.56		$30.68		$19.63	
Profit (Loss) from discontinued operations		1.81		(1.80)		(11.18)		(1.80)	
Earnings per share-basic		$5.95		$10.76		$19.50		$17.83	
Profit from continuing operations		$4.07		$12.16		$28.77		$19.04	
Profit (Loss) from discontinued operations		1.76		(1.74)		(10.20)		(1.74)	
Earnings per share-diluted		$5.83		$10.42		$18.57		$17.30	

(The accompanying notes are an integral part of the consolidated financial statements.)

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEEMENTS OF CHANGES IN EQUITY

Unit: Thousands of New Taiwan Dollars

Items	Capital			Capital surplus	Retained earnings		Other equity			Treasury stock	Total	Non-controlling interests	Equity Total
	Common stock	Advance receipts for capital stock	Stock dividends to be distributed		Legal reserve	Unappropriated earnings	Exchange differences resulting from translating the financial statements of foreign operations	Unrealized gain (Loss) on financial assets at fair value through other comprehensive income	Remeasurements of the net defined benefit plan				
Balance as of January 1, 2024	$1,014,128	$853	$-	$3,318,350	$355,501	$4,373,116	$76,395	$(4,900)	$2,312	$(50,968)	9,084,787	$2,681,024	$11,765,811
Appropriation and distribution of 2023 retained earnings													
Legal reserve	-	-	-	-	303,014	(303,014)	-	-	-	-	-	-	-
Cash dividends	-	-	-	-	-	(1,214,798)	-	-	-	-	(1,214,798)	-	(1,214,798)
Net income for the six months ended June 30, 2024	-	-	-	-	-	1,801,458	-	-	-	-	1,801,458	69,332	1,870,790
Other comprehensive income for the six months ended June 30, 2024	-	-	-	-	-	-	122,399	15,166	-	-	137,565	49	137,614
Total comprehensive income	-	-	-	-	-	1,801,458	122,399	15,166	-	-	1,939,023	69,381	2,008,404
Conversion of convertible bonds	3	(1)	-	24	-	-	-	-	-	-	26	-	26
Treasury stock purchases	-	-	-	-	-	-	-	-	-	(389,127)	(389,127)	-	(389,127)
Adjustment to share of changes in equities of subsidiaries	-	-	-	(5,408)	-	-	-	-	-	-	(5,408)	88,344	82,936
Share-based payment transactions-exercise of stock option	1,370	(760)	-	6,009	-	-	-	-	-	-	6,619	-	6,619
Share-based payment transactions-stock based compensation	-	-	-	62,608	-	-	-	-	-	-	62,608	7,646	70,254
Change in non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(38,391)	(38,391)
Other-treasury shares sold to employees	-	-	-	3,409	-	-	-	-	-	1,239	4,648	-	4,648
Balance as of June 30, 2024	$1,015,501	$92	$-	$3,384,992	$658,515	$4,656,762	$198,794	$10,266	$2,312	$(438,856)	$9,488,378	$2,808,004	$12,296,382
Balance as of January 1, 2025	$1,030,852	$2,267	$-	$4,408,236	$658,515	$6,448,405	$342,338	$17,793	$2,177	$(43,181)	$12,867,402	$2,144,163	$15,011,565
Effects of retrospective application and retrospective restatement	-	-	-	-	-	(86,494)	(1,742)	-	-	-	(88,236)	-	(88,236)
Equity at beginning of period after adjustments	$1,030,852	$2,267	$-	$4,408,236	$658,515	$6,361,911	$340,596	$17,793	$2,177	$(43,181)	$12,779,166	$2,144,163	$14,923,329
Appropriation and distribution of 2024 retained earnings													
Legal reserve	-	-	-	-	361,111	(361,111)	-	-	-	-	-	-	-
Cash dividends	-	-	-	-	-	(1,448,922)	-	-	-	-	(1,448,922)	-	(1,448,922)
Stock dividends	-	-	206,828	-	-	(206,828)	-	-	-	-	-	-	-
Changes in equity of associates and joint ventures accounted for using equity method	-	-	-	1,009	-	-	-	-	-	-	1,009	-	1,009
Net income for the six months ended June 30, 2025	-	-	-	-	-	2,015,942	-	-	-	-	2,015,942	27,972	2,043,914
Other comprehensive income for the six months ended June 30, 2025	-	-	-	-	-	-	(1,499,947)	(3,945)	-	-	(1,503,892)	(1,000)	(1,504,892)
Total comprehensive income	-	-	-	-	-	2,015,942	(1,499,947)	(3,945)	-	-	512,050	26,972	539,022
Conversion of convertible bonds	2,047	13	-	121,458	-	-	-	-	-	-	123,518	-	123,518
Conversion of convertible bonds-from advance receipts of capital stock	230	(230)	-	-	-	-	-	-	-	-	-	-	-
Treasury stock purchases	-	-	-	-	-	-	-	-	-	(23,677)	(23,677)	-	(23,677)
Disposal of subsidiaries	-	-	-	-	-	-	-	-	-	-	-	(45,293)	(45,293)
Difference between consideration and carrying amount of subsidiaries acquired or disposed	-	-	-	(8,567)	-	-	-	-	-	-	(8,567)	(919)	(9,486)
Adjustment to share of changes in equities of subsidiaries	-	-	-	98	-	-	-	-	-	-	98	-	98
Share-based payment transactions-exercise of stock option	2,008	465	-	45,047	-	-	-	-	-	-	47,520	-	47,520
Share-based payment transactions-stock based compensation	-	-	-	44,270	-	-	-	-	-	-	44,270	4	44,274
Share-based payment transactions-conversion of stock option	2,037	(2,037)	-	-	-	-	-	-	-	-	-	-	-
Share-based payment transactions-purchase of stock option	-	-	-	(39,372)	-	-	-	-	-	-	(39,372)	-	(39,372)
Change in non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(53,209)	(53,209)
Other-treasury shares sold to employees	-	-	-	7,136	-	-	-	-	-	2,212	9,348	-	9,348
Balance as of June 30, 2025	$1,037,174	$478	$206,828	$4,579,315	$1,019,626	$6,360,992	$(1,159,351)	$13,848	$2,177	$(64,646)	$11,996,441	$2,071,718	$14,068,159

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translation of Financial Statements Originally Issued in Chinese

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEEMENTS OF CASH FLOWS

Unit: Thousands of New Taiwan Dollars

Items	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Cash flows from operating activities:		
Net income from continuing operations	$3,572,795	$2,590,946
Total loss from discontinued operations	(1,433,655)	(182,089)
Net income	2,139,140	2,408,857
Adjustments for:		
Income and expense adjustments:		
Depreciation	365,928	278,034
Amortization	191,540	164,937
Net (gain) or loss on financial assets or liabilities measured at fair value through profit or loss	29,658	(13,882)
Interest expense	237,499	174,444
Interest income	(16,190)	(27,801)
Share-based payment expenses	44,274	70,254
Share of profit of associates and joint ventures accounted for using the equity method	221,986	165
Loss on disposal of property, plant and equipment	118	104
Property, plan and equipment transferred to expenses	169	-
Gain on disposal of intangible assets	(34,826)	-
Gain on disposal of investments accounted for using equity method	(2,590,654)	-
Impairment loss on non-financial assets	155,892	-
Unrealized profis on sales	200	73
Realized profit on from sales	(83)	-
Other－bargain purchase gain	-	(712,211)
Others	7,308	11,388
Total income and expense adjustments:	(1,387,181)	(54,495)
Changes in operating assets and liabilities:		
Contract assets	(219,788)	158
Notes receivable,net	11,656	21,880
Accounts receivables,net	2,532,944	(1,481,384)
Other receivables	(103,669)	60,631
Inventories,net	1,677,526	(268,692)
Prepayments	119,934	126,577
Other current assets	(47,491)	10,577
Contract liabilities	44,863	42,032
Notes payable	(3,256)	(2,954)
Accounts payable	69,556	(537,530)
Other payables	(375,065)	(552,216)
Refund liabilities	(1,313,140)	703,032
Provisions	(96,070)	(83,595)
Other current liabilities	(12,283)	(141,787)
Other operating liabilities	(110,736)	(35,072)
Cash generated from operations	2,926,940	216,019
Interest received	16,190	27,801
Income tax paid	(238,159)	(1,099,831)
Net cash generated by (used in) operating activities	2,704,971	(856,011)

Items	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Cash flows from investing activities:		
Acquisition of financial assets measured at fair value through other comprehensive income	-	(20,000)
Acquisition of financial assets measured at amortized cost	(678)	(1,988,258)
Proceeds from disposal of financial assets at amortised cost	25,000	280,515
Acquisition of financial assets measured at at fair value through profit or loss	-	(39,254)
Disposal of financial assets measured at at fair value through profit or loss	-	233,688
Acquisition of investments accounted for using equity method	-	(1,392)
Acquisition of subsidiary (net of cash acquired)	(483,086)	(7,761,350)
Acquisition of property, plant and equipment	(292,463)	(132,093)
Proceeds from disposal of property, plant and equipment	216	66
Increase in refundable deposits	(67)	(122,352)
Acquisition of intangible assets	(40,574)	(139,582)
Proceeds from disposal of intangible assets	35,044	-
Increase in other non-current assets	(5,973)	(142,259)
Increase in prepayment for equipments	(78,569)	(63,515)
Other investing activities - loss control of subsidiaries	(1,004,262)	-
Net cash (used in) investing activities	(1,845,412)	(9,895,786)
Cash flows from financing activities:		
Increase in short-term loans	-	6,925,795
Decrease in short-term loans	(655,026)	-
Proceeds from long-term loans	-	7,195,061
Repayment of long-term loans	(521,051)	(647,321)
Repayment of the principal of lease liabilities	(53,122)	(49,214)
Decrease in other non-current liabilities	(3,006)	(61,615)
Employee stock options exercised	47,520	6,619
Treasury stock purchases	(23,677)	(389,127)
Treasury stock sold to employees	9,348	4,648
Interest paid	(129,861)	(117,881)
Net change of non-controlling interests	(1,542)	44,853
Other financing activities－purchase of stock option	(39,372)	-
Net cash (used in) generated by financing activities	(1,369,789)	12,911,818
Effect of exchange rate changes on cash and cash equivalents	(1,009,305)	296,263
Net (decrease) increase in cash and cash equivalents	(1,519,535)	2,456,284
Cash and cash equivalents at beginning of period	5,829,197	3,053,294
Cash and cash equivalents at end of period	$4,309,662	$5,509,578

(The accompanying notes are an integral part of the parent company only financial statements.)

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2025 and 2024
(Amounts are expressed in Thousands of New Taiwan Dollars, unless Otherwise Specified)

I. History and Organization

Bora Pharmaceuticals Co., Ltd. (“the Company”) was incorporated in the Republic of China (“R.O.C.”) on June 12, 2007, initially as ‘Bora International Co., LTD.’ until it was renamed in June 2013. The Company’s initial registered office and principal place of business was of 6F., No. 2, Aly. 36, Ln. 26, Ruiguang Rd., Neihu District, Taipei City, Republic of China (R.O.C.). The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO). The Company’s common shares were publicly listed on the Taiwan Stock Exchange (TWSE) on December 19, 2023.

II. The Authorization of Consolidated Financial Statements

The consolidated financial statements of the Company and its subsidiaries (collectively, the “Group”) for the six months ended June 30, 2025 and 2024 were authorized for issue by the Board of Directors on August 8, 2025.

III. Application of New and Revised International Financial Reporting Standards

(1) Changes in accounting policies resulting from applying for the first-time certain standards and amendments

The Group applied for the first time International Financial Reporting Standards, International Accounting Standards, and Interpretations issued, revised or amended which are recognized by Financial Supervisory Commission (“FSC”) and become effective for annual periods beginning on or after January 1, 2025. The adoption of these new standards and amendments had no material impact on the Group.

(2) Standards or interpretations issued, revised or amended, by International Accounting Standards Board (“IASB”) which have been endorsed by FSC, and not yet adopted by the Group as at the date when the Group’s financial statements were authorized for issue, are listed below.

Items	New, Revised or Amended Standards and Interpretations	Effective Date issued by IASB
a	IFRS 17 “*Insurance Contracts*”	January 1, 2023
b	Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7	January 1, 2026
c	Annual Improvements to IFRS Accounting Standards – Volume 11	January 1, 2026
d	Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7	January 1, 2026

(a) IFRS 17 "*Insurance Contracts*"

IFRS 17 provides a comprehensive model for insurance contracts, covering all relevant accounting aspects (including recognition, measurement, presentation and disclosure requirements). The core of IFRS 17 is the General (building block) Model, under this model, on initial recognition, an entity shall measure a group of insurance contracts at the total of the fulfilment cash flows and the contractual service margin. The carrying amount of a group of insurance contracts at the end of each reporting period shall be the sum of the liability for remaining coverage and the liability for incurred claims.

Other than the General Model, the standard also provides a specific adaptation for contracts with direct participation features (the Variable Fee Approach) and a simplified approach (Premium Allocation Approach) mainly for short-duration contracts.

IFRS 17 was issued in May 2017 and it was amended in 2020 and 2021. The amendments include deferral of the date of initial application of IFRS 17 by two years to annual beginning on or after January 1, 2023 (from the original effective date of January 1, 2021); provide additional transition reliefs; simplify some requirements to reduce the costs of applying IFRS 17 and revise some requirements to make the results easier to explain. IFRS 17 replaces an interim Standard – IFRS 4 Insurance Contracts – from annual reporting periods beginning on or after January 1, 2023.

(b) Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7

The amendments include:

(1) Clarify that a financial liability is derecognised on the settlement date and describe the accounting treatment for settlement of financial liabilities using an electronic payment system before the settlement date.
(2) Clarify how to assess the contractual cash flow characteristics of financial assets that include environmental, social and governance (ESG)-linked features and other similar contingent features.
(3) Clarify the treatment of non-recourse assets and contractually linked instruments.
(4) Require additional disclosures in IFRS 7 for financial assets and liabilities with contractual terms that reference a contingent event (including those that are ESG-linked), and equity instruments classified at fair value through other comprehensive income.

(c) Annual Improvements to IFRS Accounting Standards – Volume 11

(1) Amendments to IFRS 1
(2) Amendments to IFRS 7
(3) Amendments to Guidance on implementing IFRS 7
(4) Amendments to IFRS 9
(5) Amendments to IFRS 10
(6) Amendments to IAS 7

(d) Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7

The amendments include:

(1) Clarify the application of the ‘own-use’ requirements.
(2) Permit hedge accounting if these contracts are used as hedging instruments.
(3) Add new disclosure requirements to enable investors to understand the effect of these contracts on a company’s financial performance and cash flows.

The abovementioned standards and amendments are applicable for annual periods beginning on or after 1 January 2026 and have no material impact on the Group.

(3) Standards or interpretations issued, revised or amended, by IASB which have not been endorsed by FSC, and not yet adopted by the Group as at the date when the Group’s financial statements were authorized for issue, are listed below.

Items	New, Revised or Amended Standards and Interpretations	Effective Date issued by IASB
a	IFRS 10 “*Consolidated Financial Statements*” and IAS 28 “*Investments in Associates and Joint Ventures*” — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures	To be determined by IASB
b	IFRS 18 “*Presentation and Disclosure in Financial Statements*”	January 1, 2027
c	Disclosure Initiative – Subsidiaries without Public Accountability: Disclosures (IFRS 19)	January 1, 2027

(a) IFRS 10 “*Consolidated Financial Statements*” and IAS 28 “*Investments in Associates and Joint Ventures*” — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures

The amendments address the inconsistency between the requirements in IFRS 10 *“Consolidated Financial Statements” and IAS 28 “Investments in Associates and Joint Ventures”*, in dealing with the loss of control of a subsidiary that is contributed to an associate or a joint venture. IAS 28 restricts gains and losses arising from contributions of non-monetary assets to an associate or a joint venture to the extent of the interest attributable to the other equity holders in the associate or joint ventures. IFRS 10 requires full profit or loss recognition on the loss of control of the subsidiary. IAS 28 was amended so that the gain or loss resulting from the sale or contribution of assets that constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized in full.

IFRS 10 was also amended so that the gains or loss resulting from the sale or contribution of a subsidiary that does not constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized only to the extent of the unrelated investors’ interests in the associate or joint venture.

(b) IFRS 18 "*Presentation and Disclosure in Financial Statements*"

IFRS 18 will supersede IAS 1 "*Presentation of Financial Statements*". The main changes are as below:

(1) Improved comparability in the statement of profit or loss (income statement)
IFRS 18 requires entities to classify all items of income and expenses included in the statement of profit or loss into one of five categories: operating; investing; financing; income taxes; and discontinued operations. The first three categories are new, to improve the structure of the income statement, and requires all entities to provide new defined subtotals, including operating profit or loss. The improved structure and new subtotals will give investors a consistent starting point for analyzing entities' performance and make it easier to compare entities.

(2) Enhanced transparency of management-defined performance measures IFRS 18 requires entities to disclose explanations of those entity-specific measures that are related to the income statement, referred to as management-defined performance measures.

(3) Useful grouping of information in the financial statements
IFRS 18 sets out enhanced guidance on how to organize information and whether to provide it in the primary financial statements or in the notes. The changes are expected to provide more detailed and useful information. IFRS 18 also requires entities to provide more transparency about operating expenses, helping investors to find and understand the information they need.

(c) Disclosure Initiative – Subsidiaries without Public Accountability: Disclosures (IFRS 19)

This standard permits subsidiaries without public accountability to provide reduced disclosures when applying IFRS Accounting Standards in their financial statements. IFRS 19 is optional for subsidiaries that are eligible and sets out the disclosure requirements for subsidiaries that elect to apply it.

The abovementioned standards and interpretations issued by IASB have not yet endorsed by FSC at the date when the Group's financial statements were authorized for issue, the local effective dates are to be determined by FSC. As the Group is still currently determining the potential impact of the new or amended standards and interpretations listed under and (b), it is not practicable to estimate their impact on the Group at this point in time. The remaining new or amended standards and interpretations have no material impact on the Group.

4. Summary of material accounting policies

1. Statement of compliance

The consolidated financial statements of the Group for the six months ended June 30, 2025 and 2024 have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers ("the Regulations") and IAS 34 *Interim Financial Reporting* as endorsed and became effective by the FSC.

2. Basis of preparation

The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments that have been measured at fair value. The consolidated financial statements are expressed in thousands of New Taiwan Dollars ("NT$") unless otherwise stated.

3. Basis of consolidation

Preparation principle of consolidated financial statements

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if and only if the Group has:

a. activities of the investee;
b. exposure, or rights, to variable returns from its involvement with the investee; and
c. the ability to use its power over the investee to affect its returns.

When the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

a. the contractual arrangement with the other vote holders of the investee;
b. rights arising from other contractual arrangement;
c. the Group's voting rights and potential voting rights.

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control.

Subsidiaries are fully consolidated from the acquisition date, being the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases. The financial statements of the subsidiaries are prepared for the same reporting period as the parent Group, using uniform accounting policies. All intra-group balances, income and expenses, unrealized gains and losses and dividends resulting from intra-group transactions are eliminated in full.

A change in the ownership interest of a subsidiary, without a change of control, is accounted for as an equity transaction.

Total comprehensive income of the subsidiaries is attributed to the owners of the parent and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

If the Group loses control of a subsidiary, it:

a. derecognizes the assets (including goodwill) and liabilities of the subsidiary;
b. derecognizes the carrying amount of any non-controlling interest;
c. recognizes the fair value of the consideration received;
d. recognizes the fair value of any investment retained;
e. recognizes any surplus or deficit in profit or loss; and
f. reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss.

The consolidated entities are as follows:

			Percentage of Ownership (%)			
Investor	Subsidiary	Major business	June 30, 2025	December 31, 2024	June 30, 2024	Note
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Laboratories Inc.	Pharmaceutical contract development and manufacturing	100	100	100	
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceuticals USA Inc.	Pharmaceutical wholesale	100	100	100	
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Services Inc.	Pharmaceutical contract development and manufacturing	50	50	50	
Bora Pharmaceuticals Co., Ltd.	Bora Management Consulting Co., Ltd.	Management and consulting	100	100	100	
Bora Pharmaceuticals Co., Ltd.	Bora Biologics Co., Ltd.	Biotechnical services, research and development services and pharmaceutical manufacturing	-	98.14	62.61	Note 1 Note 2 Note 3 Note 4
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical and Consumer Health Inc.	Biotechnical research and management and consulting	100	100	100	
Bora Pharmaceuticals Co., Ltd.	TWi Pharmaceuticals, Inc.	Pharmaceutical manufacturing and wholesale	100	100	100	
Bora Pharmaceuticals Co., Ltd.	Sunway Biotech Co., Ltd.	Healthcare product research and manufacturing and sales	35.81	35.79	35.79	Note 5 Note 6
Bora Pharmaceutical Laboratories Inc.	Bora Pharmaceutical Services Inc.	Pharmaceutical contract development and manufacturing	50	50	50	
Bora Pharmaceutical Laboratories Inc.	Bora Pharmaceuticals Ophthalmic Inc.	Pharmaceutical contract development and manufacturing	100	99	98.85	Note 7 Note 8
TWi Pharmaceuticals, Inc.	TWi Pharmaceuticals USA, Inc.	Pharmaceutical wholesale	100	100	100	
Sunway Biotech Co., Ltd.	Sunway Group Holding Limited	Investment holding	100	100	100	
Sunway Biotech Co., Ltd.	Chen Run Marketing Co., Ltd	Healthcare product wholesale	51	51	51	
Sunway Biotech Co., Ltd.	Bora Health Inc.	Pharmaceutical and Healthcare product wholesale	100	100	100	
Sunway Group Holding Limited	Sunway Investment (H.K.) Limited	Investment holding	100	100	100	

Investor	Subsidiary	Major business	Percentage of Ownership (%) June 30, 2025	December 31, 2024	June 30, 2024	Note
Sunway Investment (H.K.) Limited	Sunway (Dongguan) Biotech Co., Ltd.	Healthcare product wholesale and sales	100	100	100	
Bora Health Inc.	Union Chemical & Pharmaceutical Co., Ltd.	Pharmaceutical manufacturing and wholesale	100	100	100	
Bora Pharmaceuticals USA Inc.	Bora Pharmaceutical Holdings, Inc.	Investment holding	100	100	100	
Bora Pharmaceuticals USA Inc.	Bora Pharmaceuticals Injectables Inc.	Pharmaceutical contract development and manufacturing	100	100	100	
Bora Pharmaceuticals USA Inc.	Bora Pharmaceuticals Inc.	Pharmaceutical contract development and manufacturing	100	100	100	
Bora Pharmaceutical Holdings, LLC.	Pyros Pharmaceuticals Inc.	Pharmaceutical wholesale	100	100	-	Note9
Bora Pharmaceutical Holdings, LLC.	Upsher-Smith Holdings, LLC.	Investment holding	100	100	100	
Bora Pharmaceutical Holdings, LLC.	Upsher-Smith America LLC	Investment holding	20	20	20	
Upsher-Smith Holdings, LLC.	Upsher-Smith America LLC	Investment holding	80	80	80	
Upsher-Smith America LLC	Upsher-Smith Laboratories, LLC	Pharmaceutical manufacturing and wholesale	100	100	100	

Note 1: As the optionees exercised the stock options of Bora Biologics Co., Ltd., the percentage of ownership of Bora Biologics Co., Ltd. was reduced from 65.70% to 62.61%.

Note 2: On July 26, 2024, the company issued 1,658 thousand common shares in exchange for the common shares held by other shareholders (other than the Company) of Bora Biologics Co., Ltd.. As a result, the Company's ownership increased from 62.61% to 100%.

Note 3: In August 2024, Bora Biologics Co., Ltd. issued 9,512 thousand shares, a portion of which was issued to employee which resulted the Company's ownership decreased from 100% to 98.14%.

Note 4: On January 20, 2025, the Company exchanged all its shares of Bora Biologics Co., Ltd. for the new shares issued by Tanvex Biopharma, Inc. Upon the completion of share exchange, the Company lost the control over Bora Biologics Co., Ltd. on January 20, 2025.

Note 5: The Company holds less than 50% of the voting rights of SunWay Biotech Co., Ltd. but still has control over it because the Company is the single largest shareholder of SunWay Biotech Co., Ltd. since the acquisition date while the other shareholders are relatively dispersed. As the Company has the ability to dominate major relevant activities of SunWay Biotech Co., Ltd., SunWay Biotech Co., Ltd. becomes one of the Company’s subsidiary accordingly.

Note 6: In June 2025, SunWay Biotech Co., Ltd. repurchased 24 thousand treasury shares, resulted in an increase of Company's ownership from 35.79% to 35.81%.

Note 7: In December 2024, Bora Pharmaceuticals Ophthalmic Inc. issued 10,000 thousand new shares, all of which were subscribed by Bora Pharmaceutical Laboratories Inc which resulted in an increase of the ownership from 98.85% to 99%.

Note 8: In March 2025, Bora Pharmaceutical Laboratories Inc. acquired the common shares held by other shareholders in cash and obtained 100% ownership of Bora Pharmaceuticals Ophthalmic Inc..

Note 9: On October 25, 2024, the Group's Board of Directors resolved to acquire 100% equity interests of Pyros Pharmaceuticals Inc. The acquirees has been included in the consolidated financial statements since October 25, 2024.

4. Except for the accounting policies listed below, the same accounting policies have been followed in the consolidated financial statements for the six months ended June 30, 2025 and 2024 as were applied in the preparation of the Group's consolidated financial statements for the year ended December 31, 2024. For the summary of other significant accounting policies, please refer to the consolidated financial statements for the year ended December 31, 2024.

(1) Non-current assets held for sale and discontinued operations

Non-current assets and disposal groups are classified as held for sale if their carrying amounts will be recovered through a sale transaction that is highly probable within one year from the date of classification and the asset or disposal group is available for immediate sale in its present condition. Non-current assets and disposal groups classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell.

In the consolidated statement of comprehensive income of the reporting period, and of the comparable period of the previous year, income and expenses from discontinued operations are reported separately from income and expenses from continuing operations, down to the level of profit after taxes, even when the Company retains a non-controlling interest in the subsidiary after the sale. The resulting profit or loss (after taxes) is reported separately in the statement of comprehensive income.

Property, plant and equipment and intangible assets once classified as held for sale are not depreciated or amortized.

(2) Post-employment benefits

The pension cost for an interim period was calculated on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted and disclosed for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events.

(3) Income taxes

Interim period income tax expense is accrued using the tax rate that would be applicable to expected total annual earnings, that is, the estimated average annual effective income tax rate applied to the pre-tax income of the interim period. The average annual effective income tax rate is estimated by current income tax expenses only. Deferred income tax is recognized and measured according to IAS 12 "*Income Tax*" and follows the same accounting policies of the Company's annual consolidated financial statements. When income tax rate changes occur in interim period, the effect on deferred income tax is recognized in profit or loss, other comprehensive income or equity at once.

V. Significant Accounting Judgements, Estimates and Assumptions

The same significant accounting judgments, estimates and assumptions have been applied in the consolidated financial statements for the six months ended June 30, 2025 and 2024 as were applied in the preparation of the Group's consolidated financial statements for the year ended December 31, 2024. For significant accounting judgments, estimates and assumptions, please refer to the consolidated financial statements for the year ended December 31, 2024.

VI. Details of Significant Accounts

1. Cash and cash equivalents

	June 30, 2025	December 31, 2024	June 30, 2024
Cash on hand	$1,012	$1,347	$1,091
Checking accounts and demand deposits	4,308,650	5,637,850	4,370,385
Time deposits	-	190,000	1,138,102
Total	$4,309,662	$5,829,197	$5,509,578

2. Financial assets measured at fair value through profit or loss

	June 30, 2025	December 31, 2024	June 30, 2024
Mandatorily measured at fair value through profit or loss:			
Stocks	$20,275	$20,275	$20,275
Cash surrender value of life insurance (Note)	93,015	99,165	91,249
Embedded derivative – Right of redemption of convertible bonds	10,322	4,202	1,360
Total	$123,612	$123,642	$112,884
Current	$30,597	$24,477	$21,635
Non-current	$93,015	$99,165	$91,249

Note: Cash surrender value of life insurance is an insurance that employees were insured, and the employer is the beneficiary of the insurance term. The insurance payment is the part of cash surrender value that was a deduction of current insurance expense and becomes an addition of carrying value of the surrender value of life insurance. The carrying value will be deducted when the insurance expires or is terminated.

The Group has no financial assets measured at fair value through profit or loss, pledged to others.

3. Financial assets at fair value through other comprehensive income

	June 30, 2025	December 31, 2024	June 30, 2024
Equity instrument investments measured at fair value through other comprehensive income – non-current:			
Stocks – emerging stock market	$42,270	$46,650	$-
Stocks – non-listed entities	156,224	174,806	208,258
Total	$198,494	$221,456	$208,258

The Group has no financial assets measured at fair value through other comprehensive income, pledged to others.

4. Financial assets at amortized cost

	June 30, 2025	December 31, 2024	June 30, 2024
Time deposits	$28,502	$59,666	$356,296
Restricted deposits	20,525	21,696	1,709,013
Total	$49,027	$81,362	$2,065,309
Current	$35,827	$67,862	$2,051,809
Non-current	$13,200	$13,500	$13,500

Please refer to Note VIII for more details on financial assets measured at amortized cost under pledge.

The Group follows the requirement of IFRS 9 to assess the impairment. Please refer to Note VI.24 for more details on loss allowance and Note XII for more details on credit risk management.

5. Notes receivable, net

	June 30, 2025	December 31, 2024	June 30, 2024
Notes receivable, gross	$8,228	$19,884	$32,443
Less: loss allowance	-	-	-
Total	$8,228	$19,884	$32,443

Notes receivable were not overdue and not pledged.

The Group follows the requirement of IFRS 9 to assess the impairment. Please refer to Note VI.24 for more details on credit loss and Note XII for more details on credit risk management.

6. Accounts receivable

	June 30, 2025	December 31, 2024	June 30, 2024
Accounts receivable, gross	$7,615,127	$10,194,017	$9,511,637
Less: loss allowance	(15,131)	(25,980)	(29,675)
Subtotal	7,599,996	10,168,037	9,481,962
Accounts receivable from related parties, gross	44,980	53,896	69,226
Less: loss allowance	-	-	-
Subtotal	44,980	53,896	69,226
Total	$7,644,976	$10,221,933	$9,551,188

Accounts receivable were not pledged.

The terms of accounts receivable are generally from 30 to 180 days. Please refer to Note VI.24 for more details on credit loss of accounts receivable for the six months ended June 30, 2025 and 2024. Please refer to Note XII for more details on credit risk management.

7. Inventories, net

(1) Details on net inventories are as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Raw materials	$1,342,531	$2,309,889	$1,952,875
Supplies and spares parts	229,156	237,541	134,009
Work in progress	69,152	97,525	100,313
Semi-finished goods	328,166	890,303	932,951
Finished goods	1,071,032	1,832,807	1,725,612
Merchandise	184,973	134,277	139,488
Total	$3,225,010	$5,502,342	$4,985,248

(2) Details on inventory costs recognized as expense from the Group's continuing operations are as follows:

The operating cost in relation to inventories of the Group's continuing operations includes the write-down of inventories loss to net realizable value and the reversal gain from the recovery of circumstances that previously caused inventories to be written down below cost, as presented below:

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
(Reversal gain) or loss from write-down of inventories	$(49,617)	$2,607	$237,186	$81,468

(3) No inventories were pledged.

8. Disposal groups classified as held for sale

(1) Discontinued operations

On January 20, 2025, the board of director of Upsher-Smith Laboratories, LLC, a wholly owned subsidiary of the Group, approved a plan for the closure of Plymouth area. The closure met the criteria of IFRS 5 "Non-current Assets Held for Sale and Discontinued Operations". Therefore, the disposal of the assets and liabilities of Plymouth area was classified as a disposal group held for sale, which was presented as income (loss) from discontinued operations. To present the discontinued operations of consolidated income statement for the three months and the six months ended June 30, 2025, the Group reclassified the income (loss) of discontinued operations for the three months and the six months ended June 30, 2024, in order to make the comparative period information of consolidated income statement more relevant.

The details of profit (loss) from discontinued operations and the related cash flow information are as follows:

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Loss from discontinued operations：				
Operating revenue	$337,273	$610,105	$659,141	$610,105
Operating costs	(495,196)	(626,157)	(1,806,800)	(626,157)
Gross profit (loss)	(157,923)	(16,052)	(1,147,659)	(16,052)
Sales and marketing expenses	(22,200)	(32,784)	(48,652)	(32,784)
General and administrative expenses	(25,093)	(82,829)	(56,344)	(82,829)
Research and development expenses	(23,018)	(31,812)	(28,995)	(31,812)
Operating (loss)	(228,234)	(163,477)	(1,281,650)	(163,477)
Reversal of impairment loss recognized in profit or loss	131,355	-	(155,893)	-
Other gain and (losses)	5,147	(18,612)	3,888	(18,612)
Net (loss) before income tax	(91,732)	(182,089)	(1,433,655)	(182,089)
Income tax benefit	278,989	-	278,989	-
Total comprehensive gain and (loss)	$187,257	$(182,089)	$(1,154,666)	$(182,089)

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Net cash (used in) operating activities	$(181,318)	$(101,031)	$(379,073)	$(101,031)
Effect of exchange rate changes on cash and cash equivalents	(15,307)	9,918	(16,819)	9,918
Net (decrease) in cash and cash equivalents	$(196,625)	$(91,113)	$(395,892)	$(91,113)

(2) Assets and liabilities of disposal groups held for sale

	June 30, 2025
Assets of disposal groups held for sale	$1,008,598
Liabilities directly associated with disposal groups held for sale	$87,846

	June 30, 2025
Assets of disposal groups held for sale	
Inventories, net	$559,085
Property, plant and equipment	442,061
Intangible assets	7,452
Total	$1,008,598
Liabilities directly associated with disposal groups held for sale	
Other payables	$87,846

9. Investments accounted for using the equity method

(1) The following table lists the investments accounted for using the equity method of the Group：

	June 30, 2025		December 31, 2024		June 30, 2024		
Investees	Carrying amount	Percentage of ownership (%)	Carrying amount	Percentage of ownership (%)	Carrying amount	Percentage of ownership (%)	Note
Investments in associates:							
Tanvex Biopharma, Inc.	$4,668,555	30.46	$-	-	$-	-	Note 1
GTSW BIOTECH SDN. BHD.	1,384	40.00	1,370	40.00	1,077	40.00	
Total	$4,669,939		$1,370		$1,077		

Note1：On January 20, 2025, the Group exchanged all its shares of Bora Biologics Co., Ltd. for the shares of Tanvex Biopharma, Inc. (the "Tanvex"). The Group has significant influence over Tanvex Biopharma, Inc., thus considers it as an affiliated corporation.

(2) Investments in associates

Information on the material associate of the Group:

Company name：Tanvex Biopharma, Inc.

Nature of the relationship: The Tanvex is engaged in the manufacturing or sales of products related to the Group's industry chain, and the purpose for the investment is based on considerations of upstream and downstream integration of the Group.

Principal place of business (country of incorporation)：Cayman Islands

Judgment of significant influence only: Although the Group is the largest shareholder of the Tanvex, upon comprehensive assessment, the Group does not possess majority voting rights as other shareholders can prevent the Group from dominating the relevant activities of the Tanvex through the cooperation few shared holders. Therefore, the Group does not have control over the aforementioned associate and only possesses significant influence.

Fair value of the investment in the associate when there is a quoted market price for the investment: Tanvex Biopharma, Inc. is a listed entity on the Taiwan Stock Exchange (TWSE). The fair value of the investment in Tanvex Biopharma, Inc. was NT$3,817,160 thousand as of June 30, 2025.

Reconciliation of the associate's summarized financial information presented to the carrying amount of the Group's interest in the associate:

	June 30, 2025
Current assets	$1,180,339
Non-current assets	5,714,070
Current liabilities	(542,792)
Non-current liabilities	(1,477,455)
Equity	4,874,162
Proportion of the Group's ownership	30.46%
Subtotal	1,484,670
Goodwill (Provisional)	3,183,885
Carrying amount of the investment	$4,668,555

The Group has engaged an independent 3rd party professional for the valuation of the identified net assets. As of June 30, 2025, the Group reported the difference between the cost of the investment and the fair value of the identified assets and liabilities at provisional amounts as the appraisal report was not completed as of the approval date for the Group's consolidated financial statements for the six months ended June 30, 2025.

	Three months ended June 30, 2025	Six months ended June 30, 2025
Operating revenue	$46,819	$96,681
Profit from continuing operations	(340,379)	(806,123)
Other comprehensive income, net	(338,518)	(301,288)
Total comprehensive income	$(678,897)	$(1,107,411)

(3) The company investments accounted for using equity method was NT$4,668,555 thousands at June 30, 2025, the related shares of (loss) from the associates and joint ventures accounted for using the equity method was NT$(103,731) thousands and NT$(222,199) thousands for the three months and the six months ended June 30, 2025, respectively, and the related shares of other comprehensive (loss) from the associates and joint ventures was NT$(103,147) thousands and NT$(90,739) thousands for the three months and the six month ended June 30, 2025, respectively, are solely based on the reports of other independent auditors.

(4) The investment in the affiliated corporation had no contingent liabilities or capital commitments as of June 30, 2025, December 31, 2024, and June 30, 2024, nor were there any guarantees provided.

10. Property, plant and equipment

	Land	Buildings	Machinery equipment	Other equipment	Construction in progress	Total
Cost:						
January 1, 2025	$3,823,922	$7,962,904	$5,388,004	$725,174	$527,375	$18,427,379
Additions	-	3,462	17,272	41,882	218,504	281,120
Disposals	-	-	(149,139)	(10,290)	-	(159,429)
Reclassification	-	8,306	45,251	1,454	(52,578)	2,433
Property, plant and equipment recognized as expenses	-	-	-	-	(169)	(169)
Reclassified to disposal group held for sale	(57,566)	(277,960)	(321,161)	(11,435)	(33,064)	(701,186)
Disposal of subsidiary	-	-	(422,089)	(202,371)	-	(624,460)
Exchange differences	(108,590)	(640,490)	(308,403)	(30,584)	(50,825)	(1,138,892)
June 30, 2025	$3,657,766	$7,056,222	$4,249,735	$513,830	$609,243	$16,086,796
January 1, 2024	$3,424,023	$1,944,518	$2,417,025	$396,860	$115,838	$8,298,264
Additions	-	5,867	49,738	9,953	76,583	142,141
Acquisitions through business combinations	362,973	5,360,018	2,028,647	173,255	108,070	8,032,963
Disposals	-	-	(21,715)	(1,666)	-	(23,381)
Reclassification	-	2,971	28,284	362	(31,655)	(38)
Exchange differences	29,115	91,805	41,530	3,000	3,307	168,757
June 30, 2024	$3,816,111	$7,405,179	$4,543,509	$581,764	$272,143	$16,618,706

	Land	Buildings	Machinery equipment	Other equipment	Construction in progress	Total
Depreciation and impairment:						
January 1, 2025	$-	$3,854,786	$2,579,972	$308,373	$-	$6,743,131
Depreciation	-	83,661	198,448	28,475	-	310,584
Disposals	-	-	(148,836)	(10,259)	-	(159,095)
Impairment	-	-	234,304	5,101	33,064	272,469
Reclassified	-	821	-	-	-	821
Reclassified to disposal group held for sale	-	(2,316)	(279,655)	(10,573)	(33,064)	(325,608)
Disposal of subsidiary	-	-	(121,104)	(30,843)	-	(151,947)
Exchange differences	-	(353,694)	(161,934)	(16,257)	-	(531,885)
June 30, 2025	$-	$3,583,258	$2,301,195	$274,017	$-	$6,158,470
January 1, 2024	$-	$457,461	$1,053,512	$135,943	$-	$1,646,916
Depreciation	-	57,584	149,124	18,318	-	225,026
Acquisitions through business combinations	-	3,134,038	1,178,494	124,147	-	4,436,679
Disposals	-	-	(21,702)	(1,509)	-	(23,211)
Reclassified	-	-	-	-	-	-
Exchange differences	-	47,538	22,163	2,146	-	71,847
June 30, 2024	$-	$3,696,621	$2,381,591	$279,045	$-	$6,357,257
Net carrying amount as of:						
June 30, 2025	$3,657,766	$3,472,964	$1,948,540	$239,813	$609,243	$9,928,326
December 31, 2024	$3,823,922	$4,108,118	$2,808,032	$416,801	$527,375	$11,684,248
June 30, 2024	$3,816,111	$3,708,558	$2,161,918	$302,719	$272,143	$10,261,449

(1) Buildings primarily include building structure, relevant constructions (such as air conditioning units and electrical machinery), which are depreciated over 20 to 50 years and 8 to 10 years, respectively.

(2) Please refer to Note VIII for more details on pledges of property, plant, and equipment.

(3) Please refer to Note VI.11 for the investment properties disclosure for the building acquired by the Company in 2019 for business operation and a portion of which was held for lease and the remaining portion was owner-occupied. The leased portion was recognized as investment properties.

11. Investment properties

Investment properties represent the Group's owns investment properties. The Group has entered into several commercial property leases on its own investment properties with lease terms approximately 3 years. These leases include a clause for annual rate adjustment to reflect the change in market conditions.

	Buildings
Cost:	
January 1, 2025	$19,449
Additions	-
Reclassification	(5,001)
June 30, 2025	$14,448
January 1, 2024	$19,449
Additions	-
June 30, 2024	$19,449
Depreciation and impairment:	
January 1, 2025	$3,039
Depreciation	265
Reclassification	(821)
June 30, 2025	$2,483
January 1, 2024	$2,431
Depreciation	304
June 30, 2024	$2,735
Net carrying amount as of:	
June 30, 2025	$11,965
December 31, 2024	$16,410
June 30, 2024	$16,714

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Net income from investment properties	$363	$1,104	$1,661	$2,530

Please refer to Note VIII for more details on investment properties under pledge.

Investment properties held by the Group are not measured at fair value but for which the fair value is disclosed. The fair value measurements of the investment properties are categorized within Level 3. The fair value of investment properties amounted to NT$39,823 thousand, NT$51,783 thousand and NT$53,094 thousand as of June 30, 2025, December 31, 2024 and June 30, 2024, respectively. The fair value has been determined based on valuations performed by an independent appraiser. The valuation methods applied are the income approach and comparison approach, and the related inputs are as follows:

Income approach:

	June 30, 2025	December 31, 2024	June 30, 2024
Net income margin	$115,463	$115,463	$110,741
Capitalization rate	2.09%	2.09%	2.11%

Comparison approach:

	June 30, 2025	December 31, 2024	June 30, 2024
Regional factors	98%-100%	98%-100%	98%-100%
Individual factors	89%-91%	89%-91%	89%-91%

12. Intangible assets

	Patent	Product/ distribution rights	Goodwill	Software	Drug license	Customers relationship	Others	Total
Cost:								
January 1, 2025	$206,643	$12,198,176	$3,663,751	$505,238	$3,246,459	$241,000	$3,435,544	$23,496,811
Additions	-	-	-	40,294	-	-	280	40,574
Reclassification	-	-	-	2,568	-	-	-	2,568
Disposals	-	(742,304)	-	-	-	-	-	(742,304)
Reclassified to disposal group held for sale	-	-	-	(20,056)	-	-	-	(20,056)
Disposal of subsidiary	-	-	(928,881)	(8,614)	-	-	(31,679)	(969,174)
Exchange differences	-	(1,230,600)	(69,459)	(39,588)	(105,460)	-	(356,359)	(1,801,466)
June 30, 2025	$206,643	$10,225,272	$2,665,411	$479,842	$3,140,999	$241,000	$3,047,786	$20,006,953
January 1, 2024	$206,564	$224,444	$3,010,317	$249,194	$2,254,352	$241,000	$77,059	$6,262,930
Additions	79	598	-	3,062	-	-	14,028	17,767
Acquisitions through business combinations	-	11,831,016	-	235,287	-	-	3,270,115	15,336,418
Reclassification	-	-	-	38	-	-	-	38
Exchange differences	-	173,888	-	7,883	-	-	48,198	229,969
June 30, 2024	$206,643	$12,229,946	$3,010,317	$495,464	$2,254,352	$241,000	$3,409,400	$21,847,122

	Patent	Product/ distribution rights	Goodwill	Software	Drug license	Customers relationship	Others	Total
Amortization and impairment:								
January 1, 2025	$50,243	$11,751,332	$-	$401,549	$325,718	$23,430	3,411,374	$15,963,646
Amortization	8,863	19,628	-	30,445	119,858	10,042	2,704	191,540
Disposals	-	(742,086)	-	-	-	-	-	(742,086)
Reclassified to disposal group held for sale	-	-	-	(20,056)	-	-	-	(20,056)
Impairment	-	-	-	17,577	-	-	-	17,577
Disposal of subsidiary	-	-	-	(2,966)	-	-	(31,679)	(34,645)
Exchange differences	-	(1,184,713)	-	(33,570)	(3,212)	-	(355,470)	(1,576,965)
June 30, 2025	$59,106	$9,844,161	$-	$392,979	$442,364	$33,472	$3,026,929	$13,799,011
January 1, 2024	$33,665	$224,238	$-	$145,888	$128,102	$4,458	$51,565	$587,916
Amortization	12,304	6,029	-	26,805	93,548	13,375	12,876	164,937
Acquisitions through business combinations	-	11,385,823	-	198,993	-	-	3,261,960	14,846,776
Exchange differences	-	167,438	-	5,758	-	-	47,940	221,136
June 30, 2024	$45,969	$11,783,528	$-	$377,444	$221,650	$17,833	$3,374,341	$15,820,765
Net carrying amount as of:								
June 30, 2025	$147,537	$381,111	$2,665,411	$86,863	$2,698,635	$207,528	$20,857	$6,207,942
December 31, 2024	$156,400	$446,844	$3,663,751	$103,689	$2,920,741	$217,570	$24,170	$7,533,165
June 30, 2024	$160,674	$446,418	$3,010,317	$118,020	$2,032,702	$223,167	$35,059	$6,026,357

Please refer to Note VI.26 for the amortization expense from continuing operations of intangible assets for the three months and the six months ended June 30, 2025 and 2024.

13. Impairment testing of goodwill and intangible assets with indefinite lives

The Company assesses impairment of the recoverable amount of goodwill at the end of each annual financial reporting date. This recoverable amount has been determined based on the fair value less costs of disposal. The fair value is the valuation result of the equity value calculated based on various valuation multipliers, the transaction price of similar comparable targets in the region or the use of various assets and liabilities under the cost approach.

14. Short-term loans

	June 30, 2025	December 31, 2024	June 30, 2024
Unsecured bank loans	$1,933,560	$2,597,850	$7,576,718
Secured bank loans	-	-	200,000
Total	$1,933,560	$2,597,850	$7,776,718
Interest rate	1.98%~2.67%	1.98%~5.76%	1.00%~6.74%

Please refer to Note VIII for more detail on assets pledged as collateral for the Group's short-term loans.

15. Financial liabilities measured at fair value through profit or loss

	June 30, 2025	December 31, 2024	June 30, 2024
Held for trading:			
Derivatives not designated as hedging instruments－Forward foreign exchange agreements	$1,139	$-	$292
Contingent consideration from business combination	677,545	1,063,913	324,500
Total	$678,684	$1,063,913	$324,792
Current	$450,976	$806,650	$324,792
Non-current	$227,708	$257,263	$-

16. Convertible bonds payable

	June 30, 2025	December 31, 2024	June 30, 2024
Liability component:			
Domestic unsecured convertible bonds	$1,370,500	$1,495,800	$1,699,700
Overseas unsecured convertible bond	7,327,783	7,327,783	-
(Discounts) premium on convertible bonds payable	(946,783)	(1,064,678)	(144,586)
Subtotal	7,751,500	7,758,905	1,555,114
Less: current portion	-	-	-
Net	$7,751,500	$7,758,905	$1,555,114

Please refer to Note VI.27 for more details on the evaluation of gain and loss of embedded derivatives and the interest expenses of the convertible bonds payable.

On August 4, 2023, the Company issued 3rd zero coupon unsecured convertible bonds. The terms of the convertible bonds were evaluated to include a liability component, embedded derivatives (a call option and a put option) and an equity component (an option for conversion into issuer's ordinary shares). The terms of the bonds are as follows:

Issue amount: NT$1,700,000 thousand

Period: August 4, 2023 ~ August 4, 2028

Important redemption clauses:

a. If the closing price of the Company's common shares on the Taiwan Stock Exchange (TWSE) for a period of 30 consecutive trading days is above the conversion price by 30%, the Company may redeem the bonds at the price of the bond's part value within 30 consecutive trading days during the period from the date after three months of the bonds issue to 40 days before the maturity date.
b. The Company may redeem the bonds at the price of the bond's part value within 30 days during the period from the date after three months of the bonds issue to 40 days before the maturity date if the outstanding balance of the bonds is less than 10% of total initial issued principal amount.
c. Bondholders have the right to require the Company to redeem all or any portion of the bonds at the principal amount of the bonds with an interest (at 100.7519% of principal amount) after August 4, 2026.

Terms of Exchange:

a. Underlying Securities: Common shares of the Company
b. Exchange Period: The bonds are exchangeable at any time on or after November 5, 2023 and prior to August 4, 2028 into common shares of the Company.
c. Exchange Price and Adjustment: The exchange price was originally NT$808 per share. The exchange price will be subject to adjustments upon the occurrence of certain events set out in the indenture.
d. Redemption on the Maturity Date: On the maturity date, the Company will redeem the bonds that remain outstanding at the principal amount.

As of June 30, 2025, the bonds of NT$329,500 thousand were converted into 535 thousand common shares, of which 1 thousand shares were recognized as advance receipts for capital stock.

On September 5, 2024, the Company issued 1st zero coupon overseas unsecured convertible bonds on the Singapore Stock Exchange. The convertible bonds includes a liability component, embedded derivatives (a call option and a put option) and an equity component (an option for conversion into issuer's ordinary shares). The terms of the bonds are as follows:

Issue amount: US$200,000 thousand

Period: September 5, 2024 ~ September 5, 2029

Important redemption clauses:

a. If the closing price (based on the exchange rate at that time) of the Company's common shares on the Taiwan Stock Exchange (TWSE) for a period of 20 out of 30 consecutive trading days (in the event of a stock split or dividend distribution, the closing price used between the ex-rights or ex-dividend trading date and the ex-rights or ex-dividend record date shall first be adjusted to the price prior to the stock split or dividend distribution.) achieve the early redemption amount (as defined below), multiplied by the conversion price at that time (converted to USD using the fixed exchange rate agreed upon on the pricing date), then divided by the face value, with the resulting total amount multiplied by 130%, the Company may, redeem in whole or in part of the bonds at plus a yield of 2.75% per annum (calculated semi-annually) (hereinafter referred to as the 'early redemption amount') ,on or at any time after September 19, 2027 and on or prior to September 5, 2029.
b. The Company may redeem all, rather than part, of the remaining outstanding bonds at the early redemption amount, if more than 90% in principal amount of the bonds originally issued has been redeemed, repurchased and canceled, or converted.
c. In the event of changes in the tax laws of the Republic of China that result in an increase in the issuing company's tax burden or the need to pay additional interest or incur higher costs due to the bonds after the issuance date, the Company may redeem all, rather than part, of the bonds at the early redemption amount. Bondholders may choose not to have their bonds redeemed early by the issuing company; however, bondholders who make this choice shall not be entitled to request the issuing company to bear any additional taxes or costs.

Important Repurchase clauses:

Except in the following circumstances, bondholders may not request the issuing company to redeem all or part of their bonds before the maturity date

a. If the common shares of the issuing company are delisted from the TWSE or suspended from trading for a period equal to or exceeding 30 consecutive trading days, bondholders may request the issuing company to redeem all or part of their bonds at the face value plus interest compensation calculated at an annual rate of 2.75% (calculated semi-annually) (hereinafter referred to as the 'early put price').
b. If the Company experiences a change of control as defined in the bond trust agreement (hereinafter referred to as the ' Offering Circular '), bondholders may request the issuing company to redeem all or part of their bonds at the early put price.
c. Unless already redeemed, repurchased, and cancelled, or converted by the bondholders, bondholders may, on the third anniversary of the issuance of the bonds, request the issuing company to redeem all or part of the bonds at the early put price.
d. Bondholders exercising the aforementioned put option, and the issuing company accepting the bondholders' put requests, shall proceed in accordance with the put procedures set forth in the Offering Circular. The Company shall redeem the bonds in cash on the payment date specified in the Offering Circular

Terms of Exchange:

a. Underlying Securities: Common shares of the Company
b. Exchange Period: The bonds are exchangeable at any time on or after December 5, 2024 and prior to August 26, 2029 into common shares of the Company.
c. Exchange Price and Adjustment: The exchange price was originally NT$964.6 per share. The exchange price will be subject to adjustments upon the occurrence of certain events set out in the indenture.
d. Redemption on the Maturity Date: On the maturity date, the Company will redeem the bonds that remain outstanding at the principal amount plus an annual yield of 2.75% (calculated semi-annually).

As of June 30, 2025, none of the bonds have been converted into common shares.

17. Long-term loans

	June 30, 2025	December 31, 2024	June 30, 2024
Unsecured bank loans	$6,780,000	$7,196,000	$5,640,000
Secured bank loans	485,723	590,774	2,809,693
Less: unamortized issuance cost	(25,455)	(32,764)	(45,474)
Less: current portion	(1,622,141)	(1,189,023)	(1,277,303)
Total	$5,618,127	$6,564,987	$7,126,916
Interest rate	1.98%~2.88%	1.98%~2.88%	2.03%~7.03%
Maturity date	Due prior to December 2034	Due prior to December 2034	Due prior to December 2034

Please refer to Note VIII for more details on pledges for the loan.

18. Post-employment benefits

Defined contribution plan

Expenses from continuing operations under the defined contribution plan for the three months ended June 30, 2025 and 2024 were NT$51,528 thousand and NT$47,165 thousand, respectively. Expenses from continuing operations under the defined contribution plan for the six months ended June 30, 2025 and 2024 were NT$112,290 thousand and NT$79,192 thousand, respectively.

19. Provisions

	Onerous contracts	Decommissioning, restoration and rehabilitation costs	Employee benefits	Total
January 1, 2025	$111,196	$4,290	$261,670	$377,156
Reversal	-	-	(6,628)	(6,628)
Utilized	(59,564)	-	(29,877)	(89,441)
Disposal of subsidiary	-	-	(2,705)	(2,705)
Exchange differences	(3,680)	-	(17,572)	(21,252)
June 30, 2025	$47,952	$4,290	$204,888	$257,130
January 1, 2024	$210,107	$5,000	$146,221	$361,328
Acquisitions through business combinations	-	-	158,489	158,489
Utilized	(55,009)	-	(26,341)	(81,350)
Reversal	-	-	(2,245)	(2,245)
Exchange differences	3,835	-	4,647	8,482
June 30, 2024	$158,933	$5,000	$280,771	$444,704
June 30, 2025, current	$47,952	$4,290	$108,100	$160,342
June 30, 2025, non-current	$-	$-	$96,788	$96,788
December 31, 2024, current	$111,196	$4,290	$132,634	$248,120
December 31, 2024, non-current	$-	$-	$129,036	$129,036
June 30, 2024, current	$110,861	$5,000	$144,112	$259,973
June 30, 2024, non-current	$48,072	$-	$136,659	$184,731

Onerous contracts

Provisions are recognized for onerous contracts, based on historical experience and other known factors.

Provision for decommissioning, restoration and rehabilitation costs

The provision for decommissioning, restoration and rehabilitation costs arose from the costs incurring after the decommissioning of a facility in accordance with the term of the contract.

Employee benefits

Provisions for employee benefits are recognized for employees' cumulative and unused benefits obligations at the reporting date.

The long-term incentive plan mainly awards performance units and time units to key employees of a U.S. subsidiary every year. During the period of the incentive plan, the performance unit will grant cash rewards to employees periodically based on the degree of performance achievement, and will be paid at the end of the incentive plan period. The time unit is awarded to key employees according to the conditions of the long-term incentive plan and based on the employee's employment status.

20. Deferred compensation plan

The unrestricted deferred compensation plan provides some key employees of a U.S. subsidiary with a benefit plan in compliance with Section 409A of the U.S. Internal Revenue Code. In addition to the employer's contribution granted to employees equally over a five year period, employees can defer up to 70% of their basic salary and up to 95% of their performance-related compensation.

	June 30, 2025	December 31, 2024	June 30, 2024
Recognized as other current liabilities	$38,598	$116,155	$36,873
Recognized as other non-current liabilities	$24,266	$57,445	$126,396

21. Equity

(1) Common stock

	June 30, 2025	December 31, 2024	June 30, 2024
Authorized shares (in thousands)	200,000	200,000	200,000
Authorized capital	$2,000,000	$2,000,000	$2,000,000
Issued and paid shares (in thousands)	103,717	103,085	101,550
Capital stock	$1,037,174	$1,030,852	$1,015,501

① Ordinary stock with par value at NT$10 per share. Each share has one voting right and is entitled to receive dividends.

② On April 12, 2024, the Board of Directors of the Company approved to issue 1,658 shares of ordinary stock with an amount of NT$16,577 thousand. In exchange for common shares held by shareholders of Bora Biologics Co., Ltd other than the company and the amendment registration was completed.

③ On August 13, 2024, the Board of Directors of the Company resolved to cancel 519 shares of treasury stock with an amount of NT$5,190 thousand. The cancellation of shares have completed the registration process.

④ For the year ended December 31, 2024, the Company's 3rd convertible bond in the amount of NT$204,000 thousand were converted to 328 ordinary shares with an amount of NT$3,284 thousand. All the converted shares have completed the registration process.

⑤ For the year ended December 31, 2024, the Company's employee stock option holders have converted 347 thousand shares at the exercise price from NT$105.3 to NT$290.7 per share to an amount of NT$3,467 thousand. All the converted shares have completed the registration process.

⑥ For the six months ended June 30, 2025, the Company's 3rd convertible bond in the amount of NT$125,300 thousand were converted to 206 thousand ordinary shares with an amount of NT$2,060 thousand, of which 205 thousand shares with an amount of NT$2,047 thousand have completed the registration process. The residual converted shares have not completed the registration process and were recognized as capital – advance receipts for ordinary share as at June 30, 2025.

⑦ For the six months ended June 30, 2025, the Company's employee stock option holders have converted 247 thousand shares at the exercise price from NT$105.3 to NT$290.7 per share to an amount of NT$2,473 thousand, of which 201 thousand shares with an amount of NT$2,008 thousand have completed the registration process. The residual converted shares have not completed the registration process and were recognized as capital – advance receipts for ordinary share as at June 30, 2025.

(2) Capital surplus

	June 30, 2025	December 31, 2024	June 30, 2024
Additional paid-in capital	$2,523,101	$2,454,021	$946,935
Conversion premium from convertible bonds	1,300,983	1,150,628	908,050
Employee stock option	193,499	212,634	177,397
Treasury stock	28,247	21,111	44,092
Difference between consideration given/ received and carrying amount of interests in subsidiaries acquired/disposed of	160,081	168,648	869,385
Increase through changes in ownership interests in subsidiaries	56,323	56,225	47,125
Changes in equity of associates and joint ventures accounted for using equity method	1,009	-	-
Equity component of convertible bonds issued	316,072	344,969	392,008
Total	$4,579,315	$4,408,236	$3,384,992

According to the R.O.C Company Act, the capital surplus shall not be used except for making good the deficit of the company. When a company incurs no loss, it may distribute the capital surplus related to the income derived from the issuance of new shares at a premium or income from endowments received by the company. The distribution could be made in cash or in the form of dividend shares to its shareholders in proportion to the number of shares being held by each of them.

(3) Treasury stock

Changes in treasury stock are as follows:

	Six Months Ended June 30			
	2025		2024	
	Number of shares (in thousand shares)	Amount	Number of shares (in thousand shares)	Amount
Beginning balance	244	$43,181	288	$50,968
Addition	36	23,677	519	389,127
Transfer to employees	(13)	(2,212)	(7)	(1,239)
Ending balance	267	$64,646	800	$438,856

(4) Retained earnings and dividend policies

According to the R.O.C Company's Articles of Incorporation, current year's earnings, if any, shall be distributed in the following order and the earnings distributions may be made on a semiannually basis:

a. Payment of all taxes and dues;
b. Offset prior years' operation losses;
c. Set aside 10% of the remaining amount after deducting items (a) and (b) as legal reserve;
d. Set aside or reverse special reserve in accordance with law and regulations; and
e. The distribution of the remaining portion, if any, is prepared by the Board of Directors and resolved in the shareholders' meeting.

The policy of dividend distribution should reflect factors such as the current and future investment environment, fund requirements, domestic and international competition and capital budgets; as well as the interest of the shareholders, share bonus equilibrium and long-term financial planning etc. The Board of Directors shall make the distribution proposal semi-annually and present it at the shareholders' meeting for approval. Generally, at least 10% of the dividends must be paid in the form of cash.

According to the Company Act in R.O.C, the Company needs to set aside amount to legal reserve unless where such legal reserve amounts to the total paid-in capital. The legal reserve can be used to offset the deficit of the Company. When the Company incurs no loss, it may distribute the portion of legal serve which exceeds 25% of the paid-in capital as dividend in stock or in cash in proportion to their share ownership permitted.

When the Company distributes distributable earnings, it shall set aside additional special reserve equivalent to the net debit balance of the component of "shareholders" equity for the current fiscal year, provided that if the company has already set aside special reserve according to the requirements for the adoption of IFRS, it shall set aside supplemental special reserve based on the difference between the amount already set aside and other net deductions from shareholders' equity. For any subsequent decrease in the deductions amount to shareholders' equity, the amount may be reversed from the special reserve. The reversed amount could be included in the distributable earnings.

The FSC on March 31, 2021 issued Order No. Financial-Supervisory-Securities-Corporate-1090150022, which sets out the following provisions for compliance: When a public company adopts for the first-time the IFRS, for any unrealized revaluation increment or cumulative translation adjustment (profit) accounted for under shareholders' equity, if it is transferred to retained earnings because the Company chooses to apply an exemption under IFRS 1, the Company shall allocate the same amount respectively in special reserve. When there is subsequently any use, disposal, or reclassification of the relevant assets, the company may reverse and book for earnings distribution the corresponding proportion originally allocated to special reserve.

Details of the 2024 and 2023 earnings distribution and dividends per share approved and resolved by shareholders' meeting held on May 23, 2025 and May 27, 2024, respectively, are as follows:

	Appropriation of earnings		Dividend per share (NT$)	
	2024	2023	2024	2023
Legal reserve	$361,111	$303,014	$-	$-
Common stock－cash dividend	1,448,922	1,414,798	14	12
Common stock－stock dividend	206,828	-	2	-

Note: The appropriation of cash dividend and payout ratio of stock divided had been adjusted as a result of the conversion of employee stock option and convertible bonds into ordinary shares.

Please refer to Note VI.26 for details on employees' compensation and remuneration to directors.

(5) Non-controlling interests

	Six Months Ended June 30	
	2025	2024
Beginning balance	$2,144,163	$2,681,024
Net income attributable to non-controlling interests	27,972	69,332
Comprehensive income attributable to non-controlling interests	(1,000)	49
Acquisition of new shares in a subsidiary not in proportionate to ownership interest	-	88,344
Difference between consideration given/ received and carrying amount of interests in subsidiaries acquired/disposed of	(919)	-
Disposal of subsidiary	(45,293)	-
Issuance of employee stock option by subsidiaries	4	7,646
Distribution of cash dividend by subsidiaries	(51,569)	(38,391)
Subsidiary's purchase of treasury stock	(1,640)	-
Ending balance	$2,071,718	$2,808,004

22. Share-based payment plans

Certain employees of the Group are entitled to share-based payment as part of their remunerations; services are provided by the employees in return for the equity instruments granted. These plans are accounted for as equity-settled share-based payment transactions.

(1) Share-based payment plan of the parent company

On November 4, 2020, January 10, 2022, May 17, 2023, and December 26, 2024, the Company was authorized by the Securities and Futures Bureau of the FSC, Executive Yuan, to issue employee share options with a total number of 1,000, 1,000,000, 1,000,000 and 1,000,000 units, respectively. Each unit entitles an optionee to subscribe for 1,000, 1, 1 and 1 shares of the Company's common shares. The exercise price of the option was set at the closing price of the Company's common share on the grant date. Only the employees of the Company and the Company's domestic and overseas subsidiaries, for which the company holds over 50% of shares with voting right on them, are eligible for the plan. The options are given to full-time employee that the optionee may exercise the options in accordance with certain schedules as prescribed by the plan starting 2 years from the grant date. Settlement upon the exercise of the options will be made through the issuance of new shares by the Company.

The contractual terms of each option granted are four and five years. There are no cash settlement alternatives.

The relevant details of the aforementioned share-based payment plan are as follows:

Date of grant	Total number of options granted (in thousand shares)	Exercise price per share (NT$) (Note)
December 29, 2020	275	$103.4
August 13, 2021	598	$145.7
May 11,2022	477	$105.8
August 31, 2022	160	$249.9
December 8, 2022	345	$285.6
September 19, 2023	535	$625.5
November 14, 2023	10	$588.6
March 11, 2024	264	$605.1
May 14, 2024	187	$687.4
November 19, 2024	4	$736.8
March 11, 2025	120	$770.2

Note: Except for various securities issued by the parent company with conversion rights or options to exchange for common stock or issuing new shares for employees' bonus, when there is a change in the common stock of the parent company (including private placement, issuance of common stock for cash, stock dividends, capital surplus reserve to capital increase, combination, company split, transfer of shares of other companies, stock split and issuance of common stock for cash to participate in the issuance of overseas depositary receipts, etc.), the exercise price shall be adjusted in accordance with the parent company's plan.

The following table lists the inputs to the model used for the aforementioned share-based payment plan:

	2021	2020
Dividend yield (%)	-	-
Expected volatility (%)	48.05%	44.36%
Risk-free interest rate (%)	0.292% ~ 0.310%	0.176% ~ 0.201%
Expected option life (Years)	3.5 ~ 4.5	3.5 ~ 4.5
Weighted average share price ($)	$277	$197
Option pricing model	Black-Scholes option pricing model	Black-Scholes option pricing model

	2022		
Dividend yield (%)	-	-	-
Expected volatility (%)	50.80% ~ 51.80%	48.02% ~ 48.84%	45.29% ~ 46.42%
Risk-free interest rate (%)	1.112% ~ 1.122%	0.992% ~ 1.027%	0.995% ~ 1.038%
Expected option life (Years)	3.0 ~ 3.5	3.0 ~ 3.5	3.0 ~ 3.5
Weighted average share price ($)	$388	$339	$161
Option pricing model	Black-Scholes option pricing model	Black-Scholes option pricing model	Black-Scholes option pricing model

	2023	
Dividend yield (%)	-	-
Expected volatility (%)	48.72% ~ 49.56%	48.72% ~ 49.56%
Risk-free interest rate (%)	1.081% ~ 1.123%	1.081% ~ 1.123%
Expected option life (Years)	3.5 ~ 4.5	3.5 ~ 4.5
Weighted average share price ($)	$646	$608
Option pricing model	Black-Scholes option pricing model	Black-Scholes option pricing model

	2024		
Dividend yield (%)	-	-	-
Expected volatility (%)	47.99% ~ 50.03%	48.24% ~ 49.59%	48.24% ~ 49.59%
Risk-free interest rate (%)	1.146% ~ 1.176%	1.431% ~ 1.476%	1.431% ~ 1.476%
Expected option life (Years)	3.5 ~ 4.5	3.5 ~ 4.5	3.5 ~ 4.5
Weighted average share price ($)	$625	$710	$750
Option pricing model	Black-Scholes option pricing model	Black-Scholes option pricing model	Black-Scholes option pricing model

	2025
Dividend yield (%)	-
Expected volatility (%)	40%
Risk-free interest rate (%)	1.497% ~ 1.596%
Expected option life (Years)	3.5 ~ 4.5
Weighted average share price ($)	$784
Option pricing model	Black-Scholes option pricing model

The expected life of the share options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may also not necessarily be the actual outcome.

The following table contains further details on the aforementioned share-based payment plan:

	Six Months Ended June 30			
	2025		2024	
	Number of options outstanding (in thousand shares)	Weighted average exercise price per share (NT$)	Number of options outstanding (in thousand shares)	Weighted average exercise price per share (NT$)
Outstanding, beginning	2,082	$390.7	2,035	$300.4
Granted	120	770.2	451	660.2
Forfeited	(12)	665.2	(15)	258.1
Exercised	(247)	188.8	(61)	108.5
Expired	-	-	-	-
Outstanding, ending	1,943	$428.7	2,410	$372.9
Exercisable, ending	517	-	263	-

The information on the outstanding stock options as of June 30, 2025 and 2024, is as follows:

	Range of exercise price per share	Weighted average remaining contractual life (Years)
As of June 30, 2025 share options outstanding	$103.4~$770.2	0.24~3.74
As of June 30, 2024 share options outstanding	$106.8~710.0	0.84~3.92

(2) Modification or cancellation of the share-based payment plan for employees

For the six months ended June 30, 2025, the Company modified its option plan to allow optionees to exercise their outstanding options in advance. The share exchange between Bora Biologics Co., Ltd. and Tanvex BioPharma Inc. resulted in the expiration of all outstanding share options of Bora Biologics Co., Ltd, totaling 1,651 shares. TWi Pharmaceuticals, Inc. purchased all the outstanding options of 1,545 thousand shares in cash.

Except for the fact that Bora Biologics Co., Ltd. modified its option plan to allow optionees to exercise their outstanding options in advance, no modification or cancellation of the share-based payment plan has occurred for the six month ended June 30, 2024.

(3) The expense recognized for employee services received during the six month ended June 30, 2025 and 2024 is shown in the following table:

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Total expense arising from equity-settled share-based payment transactions	$29,349	$26,499	$44,274	$70,254

23. Operating revenue

Analysis of revenue from contracts with customers for the three months and the six months ended June 30, 2025 and 2024 are as follows:

(1) Disaggregation of revenue:

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
From continuing operations：				
Revenue from contracts with customers				
Commercial sales	$3,261,379	$3,029,346	$5,842,760	$4,640,190
CDMO – services and manufacturing	1,591,435	1,385,984	3,487,472	2,630,451
Others	14,971	1,876	17,138	4,058
Total	$4,867,785	$4,417,206	$9,347,370	$7,274,699

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
From continuing operations：				
Timing of revenue recognition:				
At a point in time	$4,380,285	$4,171,183	$8,118,365	$6,832,838
Over time	487,500	246,023	1,229,005	441,861
Total	$4,867,785	$4,417,206	$9,347,370	$7,274,699

(2) Contract assets – current

	June 30, 2025	December 31, 2024	June 30, 2024	January 1, 2024
Commercial sales	$61,362	$152,556	$124,976	$-
CDMO – services and manufacturing	385,120	87,435	43,917	$15,111
Total	$446,482	$239,991	$168,893	$15,111

The changes in the Group’s contract assets for the six months ended June 30, 2025 were mainly attributable to changes in the stage of completion under the contracts. For the six months ended June 30, 2024, the changes primarily arose from the business combination and changes in the stage of completion under the contracts.

(3) Contract liabilities

	June 30, 2025	December 31, 2024	June 30, 2024	January 1, 2024
Commercial sales	$140,454	$91,400	$101,170	$44,189
CDMO – services and manufacturing	119,868	154,198	161,126	180,408
Others	4,333	-	4,333	-
Total	$264,655	$245,598	$266,629	$224,597
Current	$238,584	$245,598	$266,629	$224,597
Non-current	$26,071	$-	$-	$-

The major changes in the balances of contract liabilities for the six months ended June 30, 2025 and 2024 were mainly due to the increase in advance receipts from customers.

(4) The changes in the refund liabilities are as follows:

	Sales allowance and discount
Balance as of January 1, 2025	$3,908,335
Addition/(reversal)	26,904,794
Payment	(27,880,836)
Exchange differences	(337,098)
Balance as of June 30, 2025	$2,595,195

	Sales allowance and discount
Balance as of January 1, 2024	$1,866,901
Acquisitions through business combinations	2,015,856
Addition/(reversal)	16,994,687
Payment	(16,434,935)
Exchange differences	143,280
Balance as of June 30, 2024	$4,585,789

Refund liabilities represents estimated net sales related provision, including estimated chargeback, discounts, allowance and other adjustments of wholesale and production and expenses related to U.S. pharmaceutical sales taking into account historical experience and market activity.

24. Expected credit losses/ (gains)

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
From continuing operations：				
Operating expenses – expected credit losses/(gains):				
Accounts receivable	$(34)	$6,314	$(1,144)	$14,122
Other receivables	-	-	(2,988)	-
Total	$(34)	$6,314	$(4,132)	$14,122

Please refer to Note XII for more details on credit risk.

As of June 30, 2025, December 31, 2024 and June 30, 2024, the credit risk measured at amortized cost is assessed as low (the same as the assessment result in the beginning of the period). Therefore, the loss allowance is measured at an amount equal to 12-month expected credit losses. As trading counterparties which the Group transacts with are financial institutions with good credit, no allowance for losses has been provided in this period.

Provisions for contract assets and receivables, including notes receivable, accounts receivable and other receivables are estimated at an amount equal to lifetime expected credit losses. Impairment losses were assessed individually for counterparties with good credit quality. As of June 30, 2025, December 31, 2024, and June 30, 2024, the total gross accounts receivable amounted to NT$6,520,180 thousand, NT$8,529,464 thousand, and NT$8,690,438 thousand, respectively, with no allowance for doubtful accounts recognized.

The information on measuring provisions for receivables is using a provision matrix by considering counterparties' credit ratings, regions, industries, and other factors, is as follows:

June 30, 2025

		Overdue					
	Not past due	<=30 days	31-60 days	61-90 days	91-120 days	>=121 days	Total
Gross	$786,127	$120,755	$157,687	$15,034	$20,278	$48,274	$1,148,155
Loss rate	0.00%	0.00%	0.00%	0.00%	3.76%	29.75%	
Lifetime expected credit losses	(5)	-	(1)	-	(761)	(14,364)	(15,131)
Net	$786,122	$120,755	$157,686	$15,034	$19,517	$33,910	$1,133,024

December 31, 2024

		Overdue					
	Not past due	<=30 days	31-60 days	61-90 days	91-120 days	>=121 days	Total
Gross	$1,453,406	$70,230	$30,501	$35,544	$39,135	$109,517	$1,738,333
Loss rate	0.00%	0.00%	0.00%	0.00%	12.65%	19.20%	
Lifetime expected credit losses	(2)	-	(4)	-	(4,952)	(21,022)	(25,980)
Net	$1,453,404	$70,230	$30,497	$35,544	$34,183	$88,495	$1,712,353

June 30, 2024

		Overdue					
	Not past due	<=30 days	31-60 days	61-90 days	91-120 days	>=121 days	Total
Gross	$665,053	$123,765	$47,553	$71,686	$2,325	$12,486	$922,868
Loss rate	0.75%	5.27%	8.51%	2.28%	20.58%	96.44%	
Lifetime expected credit losses	(4,977)	(6,518)	(4,045)	(1,634)	(460)	(12,041)	(29,675)
Net	$660,076	$117,247	$43,508	$70,052	$1,865	$445	$893,193

The movement of loss allowance for accounts receivable and other receivables for the six months ended June 30, 2025 and 2024 are as follows:

	Accounts receivable	Other receivables
Balance as of January 1, 2025	$25,980	$6,314
Provision/(reversal)	(1,144)	(2,988)
Disposal of subsidiary	(8,746)	-
Exchange differences	(959)	-
Balance as of June 30, 2025	$15,131	$3,326
Balance as of January 1, 2024	$17,408	$3,326
Provision/(reversal)	14,122	-
Write-off	(2,595)	-
Exchange differences	740	-
Balance as of June 30, 2024	$29,675	$3,326

25. Leases

(1) Group as a lessee

The Group leases various properties, including real estate such as land and buildings and machinery and transportation equipment. The lease terms range from 3 to 17 years.

The Group's leases effect on the financial position, financial performance and cash flows are as follow:

A. Amounts recognized in the consolidated balance sheets

(a) Right-of-use assets

The carrying amount of right-of-use assets

	June 30, 2025	December 31, 2024	June 30, 2024
Land	$283,334	$264,131	$271,729
Buildings	493,061	535,430	558,135
Machinery equipment	6,341	7,144	8,723
Transportation equipment	11,705	18,800	3,911
Decommissioning liabilities	-	-	909
Total	$794,441	$825,505	$843,407

For the six months ended June 30, 2025, the Group's additions to right-of-use assets amounted to NT$161,062 thousand.

For the six months ended June 30, 2024, the Group's additions to right-of-use assets amounted to NT$52,031 thousand, arising from business combinations.

(b) Lease liabilities

	June 30, 2025	December 31, 2024	June 30, 2024
Lease liabilities	$829,741	$862,562	$874,379
Current	$90,088	$116,600	$109,070
Non-current	$739,653	$745,962	$765,309

Please refer to Note VI.27 for the interest on lease liabilities recognized during the six months ended June 30, 2025 and 2024 and refer to Note XII.5 for more details on the liquidity risk management analysis for lease liabilities.

B. Amounts recognized in the consolidated statements of comprehensive income

Depreciation charge for right-of-use assets

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
From continuing operations：				
Land	$3,781	$3,799	$7,580	$7,598
Buildings	17,999	21,380	40,067	41,695
Machinery equipment	1,075	812	1,912	812
Transportation equipment	2,685	896	5,520	1,690
Decommissioning liabilities	-	454	-	909
Total	$25,540	$27,341	$55,079	$52,704

C. Income and costs relating to leasing activities

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
From continuing operations：				
Expenses relating to short-term leases	$9,042	$4,159	$14,945	$5,225
Expenses relating to leases of low-value assets (exclude expenses relating to short-term leases of low-value assets)	330	458	709	808

D. Cash outflow relating to leasing activities

During the six months ended June 30, 2025 and 2024, the Group’s total cash outflows from continuing operations for leases amounted to NT$77,274 thousand and NT$63,799 thousand, respectively.

(2) Group as a lessor

Please refer to Note VI.11 for disclosures of the Company owned investment properties. Leases under investment properties are classified as operating leases as they do not transfer substantially all the risks and rewards incidental to ownership of underlying assets.

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
From continuing operations：				
Lease income from operating leases				
Income relating to fixed lease payments and variable lease payments that depend on an index or a rate	$5,494	$5,342	$12,338	$6,848

Please refer to Note VI.11 for the disclosure of property, plant and equipment for operating leases under IFRS 16. For operating leases entered by the Group, the undiscounted lease payments to be received and a total of the amounts for the remaining years at June 30, 2025, December 31, 2024 and June 30, 2024 are as follow:

	June 30, 2025	December 31, 2024	June 30, 2024
Not later than one year	$23,466	$19,349	$20,989
Later than one year but not later than two years	23,652	18,692	20,989
Later than two years but not later than three years	24,723	19,315	21,078
Later than three years but not later than four years	21,317	19,547	22,050
Later than four years but not later than five years	18,323	13,139	16,024
Later than five years	46,246	31,751	38,070
Total	$157,727	$121,793	$139,200

26. Summary statement of employee benefits, depreciation and amortization expenses by function are as follows:

Character \ Function	Three Months Ended June 30					
	2025			2024		
	Operating costs	Operating expenses	Total	Operating costs	Operating expenses	Total
From continuing operations：						
Employee benefits expense:						
Wages and salaries	$629,790	$448,845	$1,078,635	$503,611	$537,609	$1,041,220
Labor and health insurance	67,408	39,268	106,676	44,698	22,176	66,874
Pension costs	35,389	16,374	51,763	32,958	14,285	47,243
Other employee benefits expense	61,591	13,313	74,904	29,139	29,928	59,067
Depreciation	140,327	29,559	169,886	111,506	26,735	138,241
Amortization	38,798	15,794	54,592	26,847	19,027	45,874

Character \ Function	Six Months Ended June 30					
	2025			2024		
	Operating costs	Operating expenses	Total	Operating costs	Operating expenses	Total
From continuing operations：						
Employee benefits expense:						
Wages and salaries	$1,390,774	$942,419	$2,333,193	$852,363	$755,087	$1,607,450
Labor and health insurance	148,415	69,878	218,293	78,110	32,407	110,517
Pension costs	81,569	31,186	112,755	57,218	22,130	79,348
Other employee benefits expense	113,888	59,541	173,429	41,772	36,802	78,574
Depreciation	292,015	59,609	351,624	206,501	45,704	252,205
Amortization	76,409	31,886	108,295	85,584	37,676	123,260

According to the Articles of Incorporation of the Company, no less than 1% of profit of the current year shall be distributable as employees’ compensation and no higher than 5% of profit of the current year shall be distributable as remuneration to directors; Additionally, the Company shall distribute 0.1% to 0.5% of profit of the current year as salary adjustments or distribution of compensation for grassroots employees. However, the profit generated in current year shall be offset with Company's accumulated losses before the allocation of compensation to directors and employee. The Company may, by a resolution adopted by a majority vote at a meeting of Board of Directors attended by two-thirds of the total number of directors, have the profit distributable as employees’ compensation in the form of shares or in cash; and in addition thereto reported such distribution in the shareholders’ meeting. Information on the Board of Directors’ resolution regarding the employees’ compensation and remuneration to directors can be obtained from the “Market Observation Post System” on the website of the TWSE.

The Company accrued employees' compensation and remuneration to directors based on a percentage of net income before income tax. If there is a change in the proposed amounts after the annual consolidated financial statements are authorized for issue, the differences are recorded as a change in accounting estimate. Accrued employees' compensation and remuneration to directors are illustrated below:

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Employees' compensation	$13,834	$22,443	$44,522	$37,106
Remuneration to directors	6,917	11,221	22,261	18,553

The employees' compensation and remuneration to directors for 2024 and 2023 resolved by the Board of Directors on March 5, 2025 and March 7, 2024, respectively, and was distributed in the form of cash.

	2024	2023
Employees' compensation	$80,579	$61,228
Remuneration to directors	40,289	30,644

There is no difference between the aforementioned approved amounts and the amounts charged against earnings of 2024 and 2023, respectively.

27. Non-operating income and expenses

(1) Non-operating income and expenses

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
From continuing operations：				
Interest income	$10,170	$22,310	$16,190	$27,801
Others	32,747	10,084	42,741	11,746
Total	$42,917	$32,394	$58,931	$39,547

(2) Other gains and losses

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
From continuing operations：				
Property, plant and equipment gain (loss)	$191	$8	$(118)	$(104)
Foreign exchange gain (loss)	(252,389)	67,323	(221,034)	181,752
Gain on disposal of equity-method investments (Note 1)	-	-	2,590,654	-
(Loss) gain on financial assets at fair value through profit or loss (Note 2)	(8,271)	11,664	(29,658)	13,882
Others (losses)	643	20,138	(40,519)	20,197
Total	$(259,826)	$99,133	$2,299,325	$215,727

Note 1: The gain mainly arose from the shares exchange of Group's entire equity interest in Bora Biologics Co., Ltd. with shares of Tanvex BioPharma, Inc.

Note 2: The gain mainly resulted from the acquisition of equity interest in Pyros Pharmaceuticals Inc., in connection with the contingent consideration agreed upon with the former owners. The contingent consideration was measured using the discounted cash flow method and recognized as a financial liability at fair value through profit or loss. The fair value of the contingent consideration is remeasured at the end of each reporting period, and any resulting gain or loss is recognized in profit or loss as a gain or loss on financial assets/liabilities at fair value through profit or loss. Please refer to Note VI.31 for further details.

(3) Financial costs

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
From continuing operations：				
Interest expenses from bank borrowings	$57,660	$129,231	$119,998	$147,432
Interest expenses from bonds payable	54,744	8,403	108,936	16,761
Interest expenses from lease liabilities	4,299	4,532	8,498	8,552
Others	15	28	67	1,699
Total	$116,718	$142,194	$237,499	$174,444

28. Components of other comprehensive income ("OCI")

For the three months ended June 30, 2025:

	Arising	Reclassification	before tax	Tax benefit (Expense)	Net of tax
Not to be reclassified to profit or loss:					
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	$(11,902)	$-	$(11,902)	$2,134	$(9,768)
To be reclassified to profit or loss in subsequent periods:					
Translation differences of foreign operations	(2,121,108)	-	(2,121,108)	424,138	(1,696,970)
Total comprehensive income	$(2,133,010)	$-	$(2,133,010)	$426,272	$(1,706,738)

For the six months ended June 30, 2025:

	Arising	Reclassification	before tax	Tax benefit (Expense)	Net of tax
Not to be reclassified to profit or loss:					
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	$(5,612)	$-	$(5,612)	$876	$(4,736)
To be reclassified to profit or loss in subsequent periods:					
Translation differences of foreign operations	(1,875,114)	-	(1,875,114)	374,958	(1,500,156)
Total comprehensive income	$(1,880,726)	$-	$(1,880,726)	$375,834	$(1,504,892)

For the three months ended June 30, 2024:

	Arising	Reclassification	before tax	Tax benefit (Expense)	Net of tax
Not to be reclassified to profit or loss:					
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	$18,958	$-	$18,958	$(3,792)	$15,166
To be reclassified to profit or loss in subsequent periods:					
Translation differences of foreign operations	72,916	-	72,916	(14,590)	58,326
Total comprehensive income	$ 91,874	$-	$ 91,874	$(18,382)	$73,492

For the six months ended June 30, 2024:

	Arising	Reclassification	before tax	Tax benefit (Expense)	Net of tax
Not to be reclassified to profit or loss:					
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	$18,958	$-	$18,958	$(3,792)	$15,166
To be reclassified to profit or loss in subsequent periods:					
Translation differences of foreign operations	153,041	-	153,041	(30,593)	122,448
Total comprehensive income	$171,999	$-	$171,999	$(34,385)	$137,614

29. Income tax

The major components of income tax expense (benefit) of the Group's continuing operations for the three months and the six months ended June 30, 2025 and 2024 are as follows:

Income tax expense (benefit) recognized in profit or loss

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Current income tax expense (benefit):				
Current income tax expense	$91,672	$156,871	$354,176	$507,532
Adjustments in respect of prior periods	2,505	(1,583)	(19,786)	809
Deferred tax expense (benefit):				
Deferred tax expense (benefit) relating to origination and reversal of temporary differences	102,987	225,207	169,795	186,068
Deferred tax expense (benefit) relating to origination and (reversal) of tax loss and tax credit	(89,641)	(82,307)	(129,970)	(156,342)
Total income tax expense	$107,523	$298,188	$374,215	$538,067

Income tax relating to components of other comprehensive income

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Deferred tax expense (benefit):				
Translation differences of foreign operations	$(2,134)	$3,792	$(876)	$3,792
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	(424,138)	14,590	(374,958)	30,593
Income tax relating to other comprehensive income	$(426,272)	$18,382	$(375,834)	$34,385

The assessment of income tax returns

As of June 30, 2025, the assessment of the income tax returns of the Company and its subsidiaries are as follows:

	The assessment of income tax returns
The Company	Assessed and approved up to 2023
Union Chemical & Pharmaceutical Co., Ltd.	Assessed and approved up to 2023
Bora Health Inc.	Assessed and approved up to 2023
Bora Pharmaceutical Laboratories Inc.	Assessed and approved up to 2023
TWi Pharmaceuticals, Inc.	Assessed and approved up to 2021 (Note)
Bora Pharmaceuticals Ophthalmic Inc.	Assessed and approved up to 2023
Bora Pharmaceutical and Consumer Health Inc.	Assessed and approved up to 2023
Bora Management Consulting Co., Ltd.	Assessed and approved up to 2023
Sunway Biotech Co., Ltd.	Assessed and approved up to 2022
Chen Run Marketing Co., Ltd.	Assessed and approved up to 2023

Note: 2020 income tax return has not assessed and approved.

30. Earnings per share

Basic earnings per share amounts are calculated by dividing net profit for the year attributable to ordinary shareholders of the parent by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share amounts are calculated by dividing the net profit attributable to ordinary shareholders of the parent by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
(1) Basic earnings per share				
Profit from continuing operations attributable to ordinary shareholders of the Company (in thousand NT$)	$429,412	$1,267,410	$3,170,608	$1,983,547
Profit (Loss) from discontinued operations attributable to ordinary shareholders of the Company (in thousand NT$)	$187,257	$(182,089)	$(1,154,666)	$(182,089)
Weighted average number of ordinary shares outstanding for basic earnings per share (in thousands shares)	103,468	100,900	103,385	101,069
Basic earnings per share (NT$)				
Profit from continuing operations	$4.14	$12.56	$30.68	$19.63
Profit (Loss) from discontinued operations	$1.81	$(1.80)	$(11.18)	$(1.80)

If basic earnings per share are adjusted retrospectively to reflect the effect of the stock dividend distribution, the pro forma information is as follows:

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
(1) Basic earnings per share				
Profit from continuing operations attributable to ordinary shareholders of the Company (in thousand NT$)	$429,412	$1,267,410	$3,170,608	$1,983,547
Profit (Loss) from discontinued operations attributable to ordinary shareholders of the Company (in thousand NT$)	$187,257	$(182,089)	$(1,154,666)	$(182,089)
Weighted average number of ordinary shares outstanding for basic earnings per share (in thousands shares)	124,140	121,466	124,040	121,261
Basic earnings per share (NT$)				
Profit from continuing operations	$3.46	$10.43	$25.56	$16.36
Profit (Loss) from discontinued operations	$1.51	$(1.50)	$(9.31)	$(1.50)

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
(2) Diluted earnings per share				
Profit from continuing operations attributable to ordinary shareholders of the Company (in thousand NT$)	$429,412	$1,267,410	$3,170,608	$1,983,547
Interest expense from convertible bonds (in thousand NT$)	5,543	6,723	87,149	13,409
Profit from continuing operations attributable to ordinary equity holders of the Company after dilution (in thousand NT$)	$434,955	$1,274,133	$3,257,757	$1,996,956
Profit (Loss) from discontinued operations attributable to ordinary shareholders of the Company (in thousand NT$)	$187,257	$(182,089)	$(1,154,666)	$(182,089)
Weighted average number of ordinary shares outstanding for basic earnings per share (in thousand shares)	103,468	100,900	103,385	101,069
Effect of dilution:				
Employee compensation－stock (in thousand shares)	54	45	86	75
Employee stock options (in thousand shares)	774	1,032	774	1,032
Convertible bonds (in thousand shares)	2,268	2,732	8,997	2,732
Weighted average number of ordinary shares outstanding after dilution (in thousand shares)	106,564	104,709	113,242	104,908
Diluted earnings per share (NT$)				
Profit from continuing operations	$4.07	$12.16	$28.77	$19.04
Profit (Loss) from discontinued operations	$1.76	$(1.74)	$(10.20)	$(1.74)

If basic earnings per share are adjusted retrospectively to reflect the effect of the stock dividend distribution, the pro forma information is as follows:

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
(2) Diluted earnings per share				
Profit from continuing operations attributable to ordinary shareholders of the Company (in thousand NT$)	$429,412	$1,267,410	$3,170,608	$1,983,547
Interest expense from convertible bonds (in thousand NT$)	5,543	6,723	87,149	13,409
Profit from continuing operations attributable to ordinary equity holders of the Company after dilution (in thousand NT$)	$434,955	$1,274,133	$3,257,757	$1,996,956
Profit (Loss) from discontinued operations attributable to ordinary shareholders of the Company (in thousand NT$)	$187,257	$(182,089)	$(1,154,666)	$(182,089)
Weighted average number of ordinary shares outstanding for basic earnings per share (in thousand shares)	124,140	121,466	124,040	121,261
Effect of dilution:				
Employee compensation－stock (in thousand shares)	54	45	86	75
Employee stock options (in thousand shares)	774	1,044	774	1,044
Convertible bonds (in thousand shares)	2,295	2,845	9,131	2,845
Weighted average number of ordinary shares outstanding after dilution (in thousand shares)	127,263	125,400	134,031	125,225
Diluted earnings per share (NT$)				
Profit from continuing operations	$3.42	$10.16	$24.31	$15.95
Profit (Loss) from discontinued operations	$1.47	$(1.45)	$(8.61)	$(1.45)

There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date the consolidated financial statements were authorized for issue.

31. Business combinations

Acquisition of Upsher-Smith Laboratories, LLC

In order to significantly enhance CDMO business competitiveness and develop generic businesses via specialty distribution channel, the Company acquired 100% equity interest of Sawai America Holdings Inc. and 20% interest in Sawai America LLC on April 2, 2024 (April 1, 2024, Eastern time) and ultimately, obtaining 100% ownership of Upsher-Smith Laboratories, LLC (the "USL").

The fair values of the identifiable assets and liabilities of Sawai America Holdings Inc., Sawai America LLC, and its subsidiaries at the acquisition date were as follows:

	Fair value recognized at the acquisition date
Asset	
Cash and cash equivalents	$381,350
Contract assets	153,940
Accounts receivable	4,110,930
Other receivables	421,782
Inventories	2,559,103
Prepayments	277,720
Financial assets measured at fair value through profit or loss, non-current	315,155
Financial assets measured at fair value through other comprehensive income, non-current	159,203
Property, plant and equipment	3,596,284
Right-of-use assets	52,031
Intangible assets	489,642
Other non-current assets	2,686
Subtotal	12,519,826

	Fair value recognized at the acquisition date
Liabilities	
Accounts payable	942,148
Other payables	1,418,268
Income tax payable	8,790
Refund liabilities	2,015,856
Provisions	158,490
Other current liabilities - current	179,940
Lease liabilities	52,610
Other non-current liabilities	161,468
Subtotal	4,937,570
Identifiable net assets	$7,582,256

Bargain purchase gain is as follows:	
Acquisition considerations	$6,870,045
Less: identifiable net assets at fair value	(7,582,256)
Bargain purchase gain	$(712,211)

Acquisition considerations

Cash	$6,570,643
Other receivables	(304,562)
Other payables	284,164
Contingent consideration	319,800
Total consideration	$6,870,045

Analysis of cash flows on acquisition:	
Cash	$(6,870,045)
Other receivables	(304,562)
Other payables	284,164
Contingent consideration	319,800
Net cash acquired through acquisition	381,350
Net cash flow on acquisition	$(6,189,293)

The fair value of the accounts receivable amounted to NT$4,110,930 thousand in which no impairment incurred and a full collection amount was expected. Intangible assets, including drug licenses and product distribution right, were amortized on a straight-line basis over the estimated economic lives.

Contingent Considerations

As part of the share purchase agreement, Bora Pharmaceutical Holdings, Inc. shall make an additional purchase cash payment to Sawai Group Holdings Co., Ltd. and Sumitomo Corporation of Americans after the first anniversary of the acquisition date, in the event that the agreed target revenue of specific products has reached US$60,700 thousand for the 12 months following the acquisition date.

The estimation of contingent consideration was based on the achievement of the operating performance of the agreed target business for the 12 months after April 1, 2024 and was fully paid in the amount of USD 10,000 thousand due to the operational performance achieve the agreed conditions.

As of the date of approval of the consolidated financial statement, the independent appraisal expert has completed the fair value assessment of the identifiable net assets of Sawai America Holdings Inc., Sawai America LLC, and its subsidiaries. The appraisal result differs from the provisional amount used by the Group in preparing the consolidated financial statements for the fiscal year of 2024. Therefore, the group has made a retrospective adjustment to decrease the bargain purchase gain recognized for the fiscal year of 2024 in accordance with the aforementioned International Financial Reporting Standards, recognizing a provisional bargain purchase gain amount of NT$798,705 thousand. The adjustments to the financial information for the comparative periods are explained as follows:

A. The difference in the provisional amount:

Consolidated financial statements for the year ended December 31, 2024

	Amounts before retrospective adjustment	Adjustment amount	Amounts after retrospective adjustment
Acquisition consideration	$6,691,993	$178,052	$6,870,045
Less: identifiable net assets at fair value	(7,490,698)	(91,558)	(7,582,256)
Bargain purchase gain	$(798,705)	$86,494	$(712,211)

B. The consolidated financial reports for the comparative periods that the group uses for retrospective adjustments are as follows:

Consolidated balance sheet for the year ended December 31, 2024 adjustments for each accounting item.

Accounting item	Amounts before retrospective adjustment	Adjustment amount	Amounts after retrospective adjustment
Assets			
Other receivables	$954,574	$(182,535)	$772,039
Other current assets	22,611,117	-	22,611,117
Total current assets	23,565,691	(182,535)	23,383,156
Intangible assets	7,444,179	93,863	7,538,042
Other non-current assets	14,589,064	-	14,589,064
Total non-current assets	22,033,243	93,863	22,127,106
Total assets	$45,598,934	$(88,672)	$45,510,262

Accounting item.	Amounts before retrospective adjustment	Adjustment amount	Amounts after retrospective adjustment
Liabilities			
Total current liabilities	$13,808,597	$-	$13,808,597
Deferred tax liabilities	1,256,297	(436)	1,255,861
Other non-current liabilities	15,522,475	-	15,522,475
Total non-current liabilities	16,778,772	(436)	16,778,336
Total liabilities	$30,587,369	$(436)	$30,586,933
Equity			
Common stock	$1,030,852	$-	$1,030,852
Advance receipts for ordinary share	2,267	-	2,267
Capital surplus	4,408,236	-	4,408,236
Retained earnings			
Legal reserve	658,515	-	658,515
Unappropriated earnings	6,448,405	(86,494)	6,361,911
Subtotal	7,106,920	(86,494)	7,020,426
Other equity	362,308	(1,742)	360,566
Treasury stock	(43,181)	-	(43,181)
Equity attributable to shareholders of the parent	12,867,402	(88,236)	12,779,166
Non-controlling interests	2,144,163	-	2,144,163
Total equity	$15,011,565	$(88,236)	$14,923,329
Total liabilities and equity	$45,598,934	$(88,672)	$45,510,262

Acquisition of the CDMO Business and asset of Cangene bioPharm, LLC

In order to accelerate the expansion of CDMO business and utilize the capacity of the Group's operational assets to assist clients in the development of biotechnology pharmaceuticals and the commercial production of their products, the Company, through its subsidiary Bora Pharmaceuticals Injectables Inc., acquired the operational assets and CDMO business located in Baltimore, Maryland, USA from Cangene BioPharma, LLC at August 20, 2024.

The fair values of the identifiable assets and liabilities acquired from Cangene bioPharma, LLC at the acquisition date were:

	Fair value recognized at the acquisition date (Provisional amount)
Asset	
Contract assets	406,309
Accounts receivable	405,264
Inventories	403,836
Prepayments	13,540
Property, plant and equipment	1,521,549
Right-of-use assets	22,181
Deferred tax assets	3,601
Other non-current assets	3,567
Subtotal	2,779,847
Liabilities	
Accounts payable	127,878
Other payables	206,599
Contract liabilities	1,693
Lease liabilities	24,933
Deferred tax liabilities	357,326
Subtotal	718,429
Identifiable net assets	$2,061,418

Bargain purchase gain is as follows:	
Acquisition considerations	$1,111,040
Less: identifiable net assets at fair value	(2,061,418)
Bargain purchase gain	$(950,378)

Acquisition considerations

Cash	$1,111,040

Analysis of cash flows on acquisition:	
Net cash flow on acquisition	$(1,111,040)

The fair value of accounts receivable were NT$405,264 thousand, with a total contract amount of NT$418,872 thousand. The estimated uncollectible contract cash flows as of the acquisition date was NT$13,608 thousand.

The Group has engaged an independent 3rd party professional for the valuation of the identified net assets. As of June 30, 2025, the Group reported the fair value of the identified net assets at provisional amounts as the appraisal report was not completed as of the approval date for the Group's consolidated financial statements for the six months ended June 30, 2025.

Acquisition of the Pyros Pharmaceuticals Inc.

In order to accelerate the expansion of product portfolio, the Company acquired all the shares of Pyros Pharmaceuticals Inc. at October 25, 2024 through its subsidiary, Bora Pharmaceutical Holdings Inc., to obtain key rare disease brand medications.

The fair values of the identifiable assets and liabilities acquired from Pyros Pharmaceuticals Inc at the acquisition date were:

	Fair value recognized at the acquisition date (Provisional amount)
Assets	
Cash and cash equivalents	$21,784
Financial assets measured at fair value through profit or loss, current	178
Accounts receivable, net	39,737
Inventories, net	40,134
Prepayments	22,858
Intangible assets	970,470
Property, plant and equipment	624
Right-of-use assets	17,642
Subtotal	1,113,427
Liabilities	
Accounts payable	18,368
Other payables	170,547
Refund liabilities	12,281
Lease liabilities	17,642
Provisions	8,900
Subtotal	227,738
Identifiable net assets	$885,689

Goodwill is as follows:	
Acquisition considerations	$1,524,872
Less：identifiable net assets	(885,689)
Goodwill	$639,183

Acquisition considerations

Cash	$812,196
Contingent consideration	712,676
Total	$1,524,872

Analysis of cash flows on acquisition:	
Cash	$(1,524,872)
Contingent consideration	712,676
Net cash acquired through acquisition	21,784
Net cash flow on acquisition	$(790,412)

The fair value of the accounts receivable amounted to NT$39,737 thousand in which no impairment incurred and a full collection amount was expected. Intangible assets, including drug licenses and product distribution right, were amortized on a straight-line basis over the estimated economic lives.

Contingent consideration

As part of the share purchase agreement, Bora Pharmaceutical Holdings, Inc. shall make an additional purchase cash payment to Pyros Pharmaceuticals Inc.'s former shareholders.

The estimation of contingent consideration was based on the achievement of the operating performance of the agreed target business for 5 to 9 years. As of June 30, 2025, Bora Pharmaceutical Holdings, Inc. paid the earnout payment of USD 564 thousand. The estimated fair value of future contingent consideration was US$23,124 thousand (approximately NT$677,545 thousand) and recognized as financial liabilities measured at fair value through profit or loss, current and financial liabilities measured at fair value through profit or loss, non-current.

The Group has engaged an independent 3rd party professional for the valuation of the identified net assets. As of June 30, 2025, the Group reported the fair value of the identified net assets at provisional amounts as the appraisal report was not completed as of the approval date for the Group's consolidated financial statements for the six months ended June 30, 2025.

VII. Related Party Transactions

Information of the related parties that had transactions with the Group during the financial reporting periods is as follows:

Name and nature of relationship of the related parties

Name of the related parties	Nature of relationship of the related parties
3T TECHNOLOGY Co., Ltd.	Substantive related party
Galilee Biotech Ltd.("Galilee")	Substantive related party
GTSW BIOTECH SDN. BHD. ("GTSW")	Associates
Tanvex BioPharma, Inc. ("Tanvex") (Note 1)	Associates

Note 1：The assets swaps between Bora Biologics Co., Ltd. and Tanvex BioPharma, Inc. was completed on January 20, 2025. Since then, the Group has significant influence over Tanvex BioPharma, Inc., which has been classified as an associate. Therefore, the Group only disclosed the transactions with Tanvex BioPharma, Inc. after January 2025.

Significant transactions with the related parties

1. Operating revenue

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
3T TECHNOLOGY Co., Ltd.	$62,811	$65,645	$109,926	$133,544
G T S W	634	298	939	298
Total	$63,445	$65,943	$110,865	$133,842

The sales prices to the above related parties were not significantly different from those of sales to third parties. The collection term is net 60 days, which is close to the term offered to third parties.

2. Accounts receivable - related parties

	June 30, 2025	December 31, 2024	June 30, 2024
3T TECHNOLOGY Co., Ltd.	$44,374	$53,896	68,928
G T S W	606	-	298
Less: loss allowance	-	-	-
Total	$44,980	$53,896	$69,226

3. Other receivables - related party

	June 30, 2025	December 31, 2024	June 30, 2024
Tanvex	$17,103	$-	$-

4. Other payables - related parties

	June 30, 2025	December 31, 2024	June 30, 2024
Galilee	$14,533	$3,682	$7,385
Tanvex	6,875	-	-
Total	$21,408	$3,682	$7,385

5. Sales and marketing expenses

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Galilee	$12,289	$9,173	$28,583	$14,984

6. Research and development expenses

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Tanvex	$2,774	$-	$7,298	$-

7. Key management personnel compensation

	Three Months Ended June 30		Six Months Ended June 30	
	2025	2024	2025	2024
Short-term employee benefits	$71,440	$8,503	$79,488	$73,326
Post-employment benefits	135	135	270	270
Total	$71,575	$8,638	$79,758	$73,596

VIII. Assets Pledged as Security

The following table lists assets of the Group pledged as security:

	Carrying amount			
Items	June 30, 2025	December 31, 2024	June 30, 2024	Secured liabilities
Financial assets measured at amortized cost	$20,525	$21,696	$1,709,013	Customs deposit; guarantee bond with Science Park Administration;
Property, plant and equipment - land	2,250,190	3,162,990	3,565,298	Short-term loans and long-term loans
Property, plant and equipment - buildings	829,257	852,246	2,751,948	Short-term loans and long-term loans
Investment properties	11,965	16,410	16,714	Long-term loans
Refundable deposits	-	-	120,875	Lodged at Courts
Total	$3,111,937	$4,053,342	$8,163,848	

IX. Significant Contingencies and Unrecognized Contractual Commitments

Contracted capital expenditures at the balance sheet date but not yet incurred are as follows:

Company Name	Significant Contract	June 30, 2025
SunWay Biotech Co., LTD.	Property, plant and equipment	$97,623

X. Losses due to Major Disasters

None.

XI. Significant Subsequent Events

None.

XII. Others

1. Financial instruments

Financial assets

	June 30, 2025	December 31, 2024	June 30, 2024
Financial assets measured at fair value through profit or loss:			
Mandatorily measured at fair value through profit or loss	$123,612	$123,642	$112,884
Financial assets measured at fair value through other comprehensive income	198,494	221,456	208,258
Financial assets measured at amortized cost:			
Cash and cash equivalents (exclude cash on hand)	4,308,650	5,827,850	5,508,487
Financial assets measured at amortized cost	49,027	81,362	2,065,309
Notes receivable	8,228	19,884	32,443
Accounts receivable (include related parties)	7,644,976	10,221,933	9,551,188
Other receivables	361,238	772,039	735,990
Refundable deposits	42,866	44,604	169,149
Subtotal	12,414,985	16,967,672	18,062,566
Total	$12,737,091	$17,312,770	$18,383,708

Financial liabilities

	June 30, 2025	December 31, 2024	June 30, 2024
Financial liabilities measured at amortized cost:			
Short-term loans	$1,933,560	$2,597,850	$7,776,718
Accounts and other payables (including amount recognized in other non-current liabilities)	4,680,561	4,070,662	5,305,146
Bonds payable	7,751,500	7,758,905	1,555,114
Long-term loans(including current portion)	7,240,268	7,754,010	8,404,219
Lease liabilities	829,741	862,562	874,379
Deposits received	2,349	5,152	4,497
Subtotal	22,437,979	23,049,141	23,920,073
Financial liabilities at fair value through profit or loss:			
Held for trading	1,139	-	292
Contingent considerations from business combinations	677,545	1,063,913	324,500
Subtotal	678,684	1,063,913	324,792
Total	$23,116,663	$24,113,054	$24,244,865

2. Financial risk management objectives and policies

The Group's principal financial risk management objective is to manage the market risk, credit risk and liquidity risk related to its operating activates. The Group identifies measures and manages the aforementioned risks based on the Group's policy and risk appetite.

The Group has established appropriate policies, procedures and internal controls for financial risk management. Before entering into significant transactions, due approval process by the Board of Directors and Audit Committee must be carried out based on related protocols and internal control procedures. The Group complies with its financial risk management policies at all times.

3. Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of the changes in market prices. Market prices comprise foreign currency risk and interest rate risk.

In practice, it is rarely the case that a single risk variable will change independently from other risk variable, there is usually interdependencies between risk variables. However, the sensitivity analysis disclosed below does not take into account the interdependencies between risk variables.

Foreign currency risk

The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (when revenue or expense are denominated in a different currency from the Group's functional currency).

The Group has certain foreign currency receivables to be denominated in the same foreign currency with certain foreign currency payables, therefore natural hedge is received. The Group also uses forward contracts to hedge the foreign currency risk on certain items denominated in foreign currencies. Hedge accounting is not applied as they did not qualify for hedge accounting criteria.

The foreign currency sensitivity analysis of the possible change in foreign exchange rates on the Group's profit is performed on significant monetary items denominated in foreign currencies as at the end of the reporting period. The Group's foreign currency risk is mainly related to the volatility in the exchange rates for USD. The sensitivity analysis is as follows:

When NTD appreciates or depreciates against USD by 1%, the profit for the six months ended June 30, 2025 and 2024 will be decreased/increased by NT$16,066 thousand and NT$46,834 thousand, respectively.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's debt instrument investments at variable interest rates, bank borrowings with fixed interest rates and floating interest rates.

The interest rate sensitivity analysis is performed on items exposed to interest rate risk as at the end of the reporting period, including investments and borrowings with variable interest rates. At the reporting date, an increase of 10 basis points of interest rate in a reporting period could cause the profit for the six months ended June 30, 2025 and 2024 to decrease by NT$7,615 thousand and NT$5,617 thousand, respectively.

If all other factors remain, while the interest rate declines, the impact on profit and loss performance for the three months ended June 30, 2025 and 2024 will be the same amount as above but at the opposite direction.

Equity price risk

The Group's domestic and overseas unlisted equity securities and the conversion rights of domestic and overseas convertible bonds are susceptible to market price risk arising from uncertainties about future values of the investment securities. The Group's equity securities are classified under financial assets measured at fair value through profit or loss or financial assets at fair value through other comprehensive income. As for the conversion rights of domestic and overseas convertible bonds not qualified for the definition of equity element, the bonds are classified as financial assets measured at fair value through profit or loss or financial liabilities measured at fair value through profit or loss, respectively. The Group manages the equity price risk through diversification and placing limits on individual and total equity instruments. Reports on the equity portfolio are submitted to the Group's senior management on a regular basis. The Group's Board of Directors reviews and approves all equity investment decisions.

Please refer to Note XII.9 for information on sensitivity analysis of financial instruments or derivatives related to financial instruments with fair value measurements classified under Level 3 of the Group.

4. Credit risk management

Credit risk is the risk that a counterparty will not meet its obligations under a contract, leading to a financial loss. The Group is exposed to credit risk from operating activities (primarily for accounts and notes receivable) and from its financing activities, including bank deposits and other financial instruments.

Credit risk is managed by each business unit subject to the Group's established policy, procedures and control relating to credit risk management. Credit limits are established for all counterparties based on their financial position, ratings from credit rating agencies, historical experience, prevailing economic condition and the Group's internal rating criteria etc. Certain counterparties' credit risk will also be managed by taking credit enhancement procedures, such as requesting for prepayment or insurance.

As of June 30, 2025, December 31, 2024 and June 30 ,2024, accounts receivable from top ten customers represent 84%, 85% and 89% of the total accounts receivable of the Group, respectively. The credit concentration risk of rest of customers is insignificant.

Credit risk from deposits with banks, fixed income securities and other financial instruments is managed by the Group's finance department in accordance with the Group's policy. The transactions with counterparties the Company entered with shall be in compliance with internal control procedures. The Group only transacts with counterparties approved by the internal control procedures, which are banks and financial institutions, companies and government entities with good credit rating. Consequently, there is no significant credit risk for these counter parties.

5. Liquidity risk management

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of cash and cash equivalents and bank borrowings. The table below summarizes the maturity profile of the Group's financial liabilities based on the contractual undiscounted payments and contractual maturity. The payment amount includes the contractual interest. The undiscounted payment related to borrowings with variable interest rates is extrapolated based on the estimated interest rate yield curve as of the end of the reporting period.

Non-derivative financial liabilities

	<= 1 year	2 to 3 years	4 to 5 years	> 5 years	Total
June 30, 2025					
Borrowings	$3,723,996	$4,087,651	$1,554,086	$209,688	$9,575,421
Accounts and other payables	4,678,889	1,672	-	-	4,680,561
Convertible bonds	-	-	8,698,283	-	8,698,283
Lease liabilities (Note)	106,236	168,725	145,732	544,541	965,234

	<= 1 year	2 to 3 years	4 to 5 years	> 5 years	Total
December 31, 2024					
Borrowings	$3,994,171	$4,651,872	$1,994,927	$232,986	$10,873,956
Accounts and other payables	4,069,007	1,655	-	-	4,070,662
Convertible bonds	-	-	8,823,583	-	8,823,583
Lease liabilities (Note)	121,913	200,709	92,881	572,966	988,469

	<= 1 year	2 to 3 years	4 to 5 years	> 5 years	Total
June 30, 2024					
Borrowings	$9,466,235	$4,297,692	$3,148,295	$256,285	$17,168,507
Accounts and other payables	5,301,836	3,310	-	-	5,305,146
Convertible bonds	-	-	1,699,700	-	1,699,700
Lease liabilities (Note)	113,320	187,517	109,284	596,077	1,006,198

Notes：Information about the maturities of lease liabilities is provided in the table below:

	Maturities					
	Less than 5 year	6 to 10 years	11 to 15 years	16 to 20 years	>21 years	Total
June 30, 2025	$420,693	$268,607	$146,990	$61,402	$67,542	$965,234
December 31, 2024	$415,503	$234,629	$203,253	$61,402	$73,682	$988,469
June 30, 2024	$410,121	$236,862	$210,448	$68,944	$79,823	$1,006,198

6. Reconciliation of liabilities arising from financing activities

Reconciliation of liabilities for the six months ended June 30, 2025:

	Short-term loans	Long-term loans	Leases liabilities	Bonds Payable	Total liabilities from financing activities
January 1, 2025	$2,597,850	$7,754,010	$862,562	$7,758,905	$18,973,327
Cash flows	(655,026)	(521,051)	(53,122)	-	(1,229,199)
Non-cash changes					
Additions	-	-	161,062	-	161,062
Disposal	-	-	(89)	-	(89)
Disposal of subsidiary	-	-	(131,073)	-	(131,073)
Conversion	-	-	-	(116,340)	(116,340)
Interest amortization	-	-	-	108,935	108,935
Others	(9,264)	7,309	(9,599)	-	(11,554)
June 30, 2025	$1,933,560	$7,240,268	$829,741	$7,751,500	$17,755,069

Reconciliation of liabilities for the six months ended June 30, 2024:

	Short-term loans	Long-term loans	Leases liabilities	Bonds Payable	Total liabilities from financing activities
January 1, 2024	$767,508	$1,815,762	$869,372	$1,538,361	$4,991,003
Cash flows	6,925,795	6,547,740	(49,214)	-	13,424,321
Non-cash changes					
Acquisition	-	-	52,611	-	52,611
Conversion	-	-	-	(9)	(9)
Interest amortization	-	-	-	16,762	16,762
Others	83,415	40,717	1,610	-	125,742
June 30, 2024	$7,776,718	$8,404,219	$874,379	$1,555,114	$18,610,430

7. Fair values of financial instruments

(1) The methods and assumptions applied in determining the fair value of financial instruments:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following methods and assumptions were used by the Group to measure or disclose the fair values of financial assets and financial liabilities:

A. The carrying amount of cash and cash equivalents, notes receivable, accounts receivable, other receivables, notes payable, accounts payable, other payables, and other current liabilities approximate their fair value due to their short maturities.
B. For financial assets and liabilities traded in an active market with standard terms and conditions, their fair value is determined based on market quotation price (including listed equity securities, beneficiary certificates, bonds and futures etc.) at the reporting date.
C. Fair value of debt instruments without market quotations, bank loans and other non-current liabilities are determined based on the counterparty prices or valuation method. The valuation method uses discounted cash flow method as a basis, and the assumptions such as the interest rate and discount rate are primarily based on relevant information of similar instrument (such as yield curves published by the Taipei Exchange, average prices for Fixed Rate Commercial Paper published by Reuters and credit risk, etc.)
D. The fair value of derivatives which are not options and without market quotations, is determined based on the counterparty prices or discounted cash flow analysis using interest rate yield curve for the contract period. Fair value of option-based derivative financial instruments is obtained using on the counterparty prices or appropriate option pricing model (for example, Black-Scholes model) or other valuation method (for example, Monte Carlo Simulation).

(2) Fair value of financial instruments measured at amortized cost

Other than the table below, the carrying amount of the Group's financial assets and financial liabilities approximate their fair value.

	Carrying amount as of		
	June 30, 2025	December 31, 2024	June 30, 2024
Financial liabilities:			
Bonds payable	$7,751,500	$7,758,905	$1,555,114

	Fair value as of		
	June 30, 2025	December 31, 2024	June 30, 2024
Financial liabilities:			
Bonds payable	$7,941,475	$7,894,046	$1,548,597

(3) Fair value measurement hierarchy for financial instruments

Please refer to Note XII.9 for fair value measurement hierarchy for financial instruments of the Group.

8. Derivative financial instruments

The related information for derivative financial instruments not qualified for hedge accounting and not yet settled at June 30, 2025, December 31, 2024 and June 30, 2024 is as follows:

Currency orwards

Items (by contract)	Notional Amount	Contract Period
June 30, 2025		
Foreign Exchange Forward Contract	Sale USD$134 thousand	June 19, 2025 To July 07, 2025
Foreign Exchange Forward Contract	Sale USD$411 thousand	June 19, 2025 To July 21, 2025
Foreign Exchange Forward Contract	Sale USD$470 thousand	June 19, 2025 To July 21, 2025
Foreign Exchange Forward Contract	Sale USD$3,823 thousand	May 26, 2025 To July 29, 2025
December 31, 2024		
There is no such circumstance.		
June 30, 2024		
Foreign Exchange Forward Contract	Sale USD$2,000 thousand	May 30, 2024 To July 01, 2024

Embedded derivatives

The Group's embedded derivatives arising from issuing convertible bonds have been separated from the host contract and carried at fair value through profit or loss. Please refer to Note VI for further information on this transaction.

9. Fair value measurement hierarchy

(1) Fair value measurement hierarchy

All asset and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole. Level 1, 2 and 3 inputs are described as follows:

Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities that the entity can access at the measurement date
Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
Level 3 – Unobservable inputs for the asset or liability

(2) Fair value measurement hierarchy of the Group's assets and liabilities

The Group does not have assets that are measured at fair value on a non-recurring basis. Fair value measurement hierarchy of the Group's assets and liabilities measured at fair value on a recurring basis is as follows:

June 30, 2025

	Level 1	Level 2	Level 3	Total
Financial assets:				
Financial assets at fair value through profit or loss:				
Stock	$-	$-	$20,275	$20,275
Cash surrender value of life insurance	-	93,015	-	93,015
Embedded derivatives	-	-	10,322	10,322
Financial assets measured at fair value through other comprehensive income:				
Equity instruments	42,270	-	156,224	198,494
Total	$42,270	$93,015	$186,821	$322,106
Financial liabilities:				
Financial liabilities at fair value through profit or loss:				
Forward currency contract	$-	$1,139	$-	$1,139
Contingent considerations from business combinations	-	-	677,545	677,545
Total	$-	$1,139	$677,545	$678,684

December 31, 2024

	Level 1	Level 2	Level 3	Total
Financial assets:				
Financial assets at fair value through profit or loss:				
Stock	$-	$-	$20,275	$20,275
Cash surrender value of life insurance	-	99,165	-	99,165
Embedded derivatives	-	-	4,202	4,202
Financial assets measured at fair value through other comprehensive income:				
Equity instruments	46,650	-	174,806	221,456
Total	$46,650	$99,165	$199,283	$345,098
Financial liabilities:				
Financial liabilities at fair value through profit or loss:				
Contingent considerations from business combinations	$-	$-	$1,063,913	$1,063,913

June 30, 2024

	Level 1	Level 2	Level 3	Total
Financial assets:				
Financial assets at fair value through profit or loss:				
Stock	$-	$-	$20,275	$20,275
Cash surrender value of life insurance	-	91,249	-	91,249
Embedded derivatives	-	-	1,360	1,360
Financial assets measured at fair value through other comprehensive income:				
Equity instruments	-	-	208,258	208,258
Total	$-	$91,249	$229,893	$321,142
Financial liabilities:				
Financial liabilities at fair value through profit or loss:				
Forward currency contract	$-	$292	$-	$292
Contingent considerations from business combinations	-	-	324,500	324,500
Total	$-	$292	$324,500	$324,792

Transfers between Level 1 and Level 2 during the period

During the six months ended June 30, 2025 and 2024, there were no transfers between Level 1 and Level 2 fair value measurements.

The detail movement of recurring fair value measurements in Level 3:

Reconciliation for fair value measurements in Level 3 of the fair value hierarchy for movements during the period is as follows:

Six months ended June 30, 2025

	Financial assets (liabilities)		
	Measured at fair value through profit or loss		
	Embedded derivatives	Contingent considerations	Stock
As of January 1, 2025	$4,202	$(1,063,913)	$20,275
Acquisition/issuance	-	-	-
Disposal/settlements/Reclassification	-	336,552	-
Gains (losses) recognized in profit or loss (presented as “gain (loss) on financial assets or liabilities measured at fair value through profit or loss”):	6,120	(39,413)	-
Exchange differences	-	89,229	-
As of June 30, 2025	$10,322	$(677,545)	$20,275

	Financial assets (liabilities)
	Measured at fair value through other comprehensive income
	Stock
As of January 1, 2025	$174,806
Acquisition/issuance	-
Transfer	-
Gains (losses) recognized in profit or loss: (presented as "Unrealized gains or (losses) from equity investments instruments measured at fair value through other comprehensive income")	(1,233)
Exchange differences	(17,349)
As of June 30, 2025	$156,224

Six months ended June 30, 2024

	Financial assets (liabilities)		
	Measured at fair value through profit or loss		
	Embedded derivatives	Contingent considerations	Stock
As of January 1, 2024	$(9,009)	$(1,935,436)	$-
Acquisition/issuance	-	(319,800)	20,275
Disposal/settlements/Reclassification	-	2,034,911	-
Gains (losses) recognized in profit or loss (presented as "gain (loss) on financial assets or liabilities measured at fair value through profit or loss"):	10,369	13,769	-
Exchange differences	-	(117,944)	-
As of June 30, 2024	$1,360	$(324,500)	$20,275

	Financial assets (liabilities)
	Measured at fair value through other comprehensive income
	Stock
As of January 1, 2024	$7,758
Acquisition/issuance	179,203
Gains (losses) recognized in profit or loss: (presented as "Unrealized gains or (losses) from equity investments instruments measured at fair value through other comprehensive income")	18,958
Exchange differences	2,339
As of June 30, 2024	$208,258

Information on significant unobservable inputs to valuation

Description of significant unobservable inputs to valuation of recurring fair value measurements categorized within Level 3 of the fair value hierarchy is as follows:

June 30, 2025

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Financial assets:					
At fair value through profit and loss:					
Stock	Market approach	discount for lack of marketability	40.00%	The higher the discount for lack of marketability, the lower the fair value of the stock	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) by NT$3,689 thousand in the Group's profit or loss.
Embedded derivatives	Binomial tree pricing method for convertible bond	Volatility	38.71%	The higher the volatility, the higher the fair value of the embedded derivatives	1% increase (decrease) in the volatility would result in an increase by NT$776 thousand or an decrease by NT$411 thousand in the Group's profit or loss.
At fair value through other comprehensive income:					
Stock	Asset-based approach	discount for lack of marketability	30%	The higher the discount for lack of marketability, the lower the fair value of the stock	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$23 thousand
Stock	Market approach	discount for lack of marketability	35%	The higher the discount for lack of marketability, the lower the fair value of the stock	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$556 thousand
Stock	Market approach	discount for lack of marketability	15.80%	The higher the discount for lack of marketability, the lower the fair value of the stock	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$17,318 thousand

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Financial liabilities:					
At fair value through profit and loss:					
Contingent Consideration	Discounted cash flow	Discount rate	15.60%	The higher the discount rate, the lower the fair value of the contingent consideration	1% increase (decrease) in the volatility would result in an increase by NT$6,718 thousand or an decrease by NT$7,011 thousand in the Group's profit or loss.

December 31, 2024:

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Financial assets：					
At fair value through profit and loss					
Stock	Market approach	discount for lack of marketability	40%	The higher the discount for lack of marketability, the lower the fair value of the stock	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) by NT$3,689 thousand in the Group's profit or loss.
Embedded derivatives	Binomial tree pricing method for convertible bond	Volatility	39.57%	The higher the volatility, the higher the fair value of the embedded derivative.	1% increase (decrease) in the volatility would result in an increase by NT$1,047 thousand or an decrease by NT$938 thousand in the Group's profit or loss.
At fair value through other comprehensive income					
Stock	Asset-based approach	discount for lack of marketability	30%	The higher the discount for lack of marketability, the lower the fair value of the stock	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$35 thousand.

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Stock	Market approach	discount for lack of marketability	35%	The higher the discount for lack of marketability, the lower the fair value of the stock	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$624 thousand.
Stock	Market approach	discount for lack of marketability	15.80%	The higher the discount for lack of marketability, the lower the fair value of the stock	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$19,378 thousand.
Financial liabilities：					
At fair value through other comprehensive income					
Contingent consideration	Discounted cash flow	Discount rate	15.60%	The higher the discount rate, the lower the fair value of the contingent consideration	1% increase (decrease) in the discount rate would result in an decrease of NT$8,059 thousand or an increase of NT$8,432 thousand in the Group's profit or loss.

June 30, 2024

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Financial assets：					
At fair value through profit and loss					
Stock	Asset-based approach	discount for lack of marketability	40%	The higher the discount for lack of marketability, the lower the fair value of the stocks	10% increase (decrease) in the discount for lack of marketability would result in an increase by NT$4,647 thousand or an decrease by NT$4,786 in the Group's profit or loss.

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Embedded derivatives	Binomial tree pricing method for convertible bond	Volatility	42.35%	The higher the volatility, the higher the fair value of the embedded derivative.	1% increase (decrease) in the volatility would result in an increase by NT$340 thousand or an decrease by NT$340 thousand in the Group's profit or loss.
At fair value through other comprehensive income					
Stock	Asset-based approach	discount for lack of marketability	30%	The higher the discount for lack of marketability, the lower the fair value of the stocks	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$42 thousand.
Stock	Market approach	discount for lack of marketability	34.16%	The higher the discount for lack of marketability, the lower the fair value of the stocks	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$410 thousand.
Stock	Market approach	discount for lack of marketability	40%	The higher the discount for lack of marketability, the lower the fair value of the stocks	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$390 thousand.

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Stock	Market approach	discount for lack of marketability	15.18%	The higher the discount for lack of marketability, the lower the fair value of the stocks	10% increase (decrease) in the discount for lack of marketability would result in decrease (increase) in the Group's equity by NT$18,856 thousand.

Valuation process used for fair value measurements categorized within Level 3 of the fair value hierarchy

The Group's Finance Department is responsible for validating the fair value measurements and ensuring that the results of the valuation are in line with market conditions, based on independent and reliable inputs which are consistent with other information, and represent exercisable prices. The Department analyses the movements in the values of assets and liabilities which are required to be re-measured or re-assessed as per the Group's accounting policies at each reporting date.

(3) Fair value measurement hierarchy of the Group's assets and liabilities not measured at fair value but for which the fair value is disclosed

June 30, 2025：

	Level 1	Level 2	Level 3	Total
Financial assets not measured at fair value but for which the fair value is disclosed:				
Investment properties	$-	$-	$39,823	$39,823

December 31, 2024：

	Level 1	Level 2	Level 3	Total
Financial assets not measured at fair value but for which the fair value is disclosed:				
Investment properties	$-	$-	$51,783	$51,783

June 30, 2024：

	Level 1	Level 2	Level 3	Total
Financial assets not measured at fair value but for which the fair value is disclosed:				
Investment properties	$-	$-	$53,094	$54,094

10. Significant assets and liabilities denominated in foreign currencies

Unit: thousands

	June 30, 2025		
	Foreign currencies	Foreign exchange rate	NTD
Financial assets			
Monetary items:			
USD	$73,577	29.30	$2,155,806
Financial liabilities			
Monetary items:			
USD	$18,743	29.30	$549,170

Unit: thousands

	December 31, 2024		
	Foreign currencies	Foreign exchange rate	NTD
Financial assets			
Monetary items:			
USD	$78,048	32.79	$2,559,194
Financial liabilities			
Monetary items:			
USD	$22,513	32.79	$738,201

Unit: thousands

	June 30, 2024		
	Foreign currencies	Foreign exchange rate	NTD
Financial assets			
Monetary items:			
USD	$186,083	32.45	$6,038,393
Financial liabilities			
Monetary items:			
USD	$41,756	32.45	$1,354,982

11. Capital management

The primary objective of the Group’s capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and maximize shareholder value. The Group manages its capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust dividend payment to shareholders, return capital to shareholders or issue new shares.

12. Other

Some accounts reported in the previous financial statements have been reclassified to facilitate comparison of the financial statements.

XIII. <u>Other Disclosure</u>

1. Information at significant transactions
   (a) Loans to others: Please refer to Table 2.
   (b) Endorsement/Guarantee provided to others: Please refer to Table 3.
   (c) Significant marketable securities held at the end of the reporting period: Please refer to Table 4.
   (d) Total purchases from or sales to related parties which exceeding the lower of NT$100 million or 20 percent of paid-in capital: Please refer to Table 5.
   (e) Receivables from related parties with amounts exceeding the lower of NT$100 million or 20 percent of paid-in capital: Please refer to Table 6.
   (f) Financial instruments and derivative transactions: Please refer to Note VI.15.

   (g) The business relationship, significant transactions and amounts between parent company and subsidiaries: Please refer to Table 1.

2. Information on investees: Please refer to Table 7.

3. Investment in Mainland China: Please refer to Table 8.

XIV. <u>Segment information</u>

For management purposes, the Group is organized into business units based on their products and services and has three reportable operating segments as follows:

Sales segment: selling pharmaceuticals, generic, and healthcare products.
CDMO segment: contract development and manufacturing organization of pharmaceuticals.
Other segment: Others.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on operating profit or loss and is measured based on accounting policies consistent with those in the consolidated financial statements. However, income taxes are managed on a group basis and are not allocated to operating segments.

Transfer prices between operating segment are on an arm’s length basis in a manner similar to transactions with third parties.

Three months ended June 30, 2025

	Sales segment	CDMO segment	Other segment	Adjustment and elimination	Consolidated
Revenue from continuing operations					
External customer	$ 3,261,379	$1,591,435	$ 14,971	$-	$ 4,867,785
Inter-segment (Note)	783,527	275,685	161,024	(1,220,236)	-
Total revenue	$ 4,044,906	$1,867,120	$175,995	$(1,220,236)	$ 4,867,785
Segment profit from continuing operations	$ 514,491	$(125,855)	$(227,019)	$ 393,778	$ 555,395

Six months ended June 30, 2025

	Sales segment	CDMO segment	Other segment	Adjustment and elimination	Consolidated
Revenue from continuing operations					
External customer	$5,842,760	$3,487,472	$17,138	$-	$9,347,370
Inter-segment (Note)	1,730,357	572,292	366,841	(2,669,490)	-
Total revenue	$7,573,117	$4,059,764	$383,979	$(2,669,490)	$9,347,370
Segment profit from continuing operations	$733,401	$201,115	$2,334,223	$304,056	$3,572,795

Three months ended June 30, 2024

	Sales segment	CDMO segment	Other segment	Adjustment and elimination	Consolidated
Revenue from continuing operations					
External customer	$3,029,346	$1,385,984	$1,876	$-	$4,417,206
Inter-segment (Note)	1,423,181	125,218	216,782	(1,765,181)	-
Total revenue	$4,452,527	$1,511,202	$218,658	$(1,765,181)	$4,417,206
Segment profit from continuing operations	$1,539,836	$372,948	$(283,801)	$(21,577)	$1,607,406

Six months ended June 30, 2024

	Sales segment	CDMO segment	Other segment	Adjustment and elimination	Consolidated
Revenue from continuing operations					
External customer	$4,640,190	$2,630,451	$4,058	$-	$7,274,699
Inter-segment (Note)	1,446,377	326,405	353,834	(2,126,616)	-
Total revenue	$6,086,567	$2,956,856	$357,892	$(2,126,616)	$7,274,699
Segment profit from continuing operations	$2,388,394	$623,899	$(374,994)	$(46,353)	$2,590,946

Note: Inter-segment revenue are eliminated under consolidation and recorded under the "adjustment and elimination" column.

(Amounts are expressed in Thousands of New Taiwan Dollars, unless Otherwise Specified)

Table 1

Significant inter-company transactions

For the six months ended June 30, 2025

No. (Note 1)	Company Name	Counter-party	Relationship with the Company (Note 2)	Transactions			
				Financial statement account	Amount	Terms	Percentage of consolidated operating revenue or consolidated total assets (Note 3)
0	Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Laboratories Inc.	1	Operating revenue	130,228	60 days from the date of invoice	1.30%
0	Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Services Inc.	1	Operating revenue	151,539	60 days from the date of invoice	1.51%
1	Bora Pharmaceutical Laboratories Inc.	TWi Pharmaceuticals, Inc.	3	Operating revenue	508,141	60 days from the date of invoice	5.08%
2	TWi Pharmaceuticals, Inc.	Upsher-Smith Laboratories, LLC	3	Accounts receivable	1,506,093	180 days from the date of invoice	3.59%
2	TWi Pharmaceuticals, Inc.	Upsher-Smith Laboratories, LLC	3	Operating revenue	1,642,725	180 days from the date of invoice	16.42%
3	TWi Pharmaceuticals USA, Inc.	Upsher-Smith Laboratories, LLC	3	Accounts receivable	970,597	180 days from the date of invoice	2.31%
3	TWi Pharmaceuticals USA, Inc.	Upsher-Smith Laboratories, LLC	3	Other receivables	509,052	(Note 5)	1.21%
4	Bora Pharmaceuticals USA Inc.	Upsher-Smith Laboratories, LLC	3	Other receivables	2,057,329	(Note 5)	4.90%
4	Bora Pharmaceuticals USA Inc.	Bora Pharmaceutical Services Inc.	3	Other revenue	130,267	60 days from the date of invoice	1.30%

Note 1: The Company and its subsidiaries are coded as follows:

(1) Parent Company is "0".

(2) The subsidiaries are numbered in order from "1".

Note 2: Transactions are categorized as follows:

(1) Parent company to subsidiary.

(2) Subsidiary to parent company.

(3) Subsidiary to subsidiary.

Note 3: The percentage with respect to the consolidated total asset or operating revenues: it is computed based on period-end balance of transaction to consolidated total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for income statement accounts.

Note 4: The Company determines whether to disclose significant transactions in this table in accordance with the principle of materiality.

Note 5: No related similar transactions can be followed, the transaction terms are agreed by both parties.

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
(Amounts are expressed in Thousands of New Taiwan Dollars, unless Otherwise Specified)

Table 2

Loans to others

No. (Note 1)	Lender	Borrower	Financial Statement account	Is a related party	Maximum outstanding balance for the period	Ending balance	Actual amount drawn down	Interest rate	Nature of loan (Note 4)	Transaction amounts (Note 5)	Reason for short-term financing (Note 6)	Loss allowance	Collateral		Limit on loans granted to a single party (Note 2)	Ceiling on total loan granted (Note 3)
													Item	Value		
1	Bora Pharmaceuticals USA Inc.	Upsher-Smith Laboratories, LLC	Other receivables	Yes	$2,224,735	$1,963,100	$1,963,100	6.0%	2	$-	Need for operation	$-	None	$-	$23,785,327	$23,785,327
2	TWi Pharmaceuticals USA, Inc.	Upsher-Smith Laboratories, LLC	Other receivables	Yes	$509,052	$509,052	$509,052	5.7%	2	$-	Need for operation	$-	None	$-	$2,249,261	$2,249,261

Note 1: The Company and its subsidiaries are coded as follows:
(1) Parent Company is "0".
(2) The subsidiaries are numbered in order from "1".

Note 2: Limit on loans granted to a single party:
(1) Business transaction: limit on loans granted to a single party shall not exceed 10% of the lender's net assets value as of the period and the accumulated business transaction amounts of the past 12 months. Transaction amounts is defined as amount the higher of sales to or purchases from.
(2) Short-term financing:
(i) Limit on loans granted to a single party shall not exceed 200% of the net assets value of Bora Pharmaceuticals USA Inc. as of the period.
(ii) Limit on loans granted to a single party shall not exceed 200% of the net assets value of TWi Pharmaceuticals USA, Inc. as of the period.

Note 3: Ceiling on total loan granted:
(1) The ceiling on total loans granted by Bora Pharmaceuticals USA Inc. to all parties shall not exceed 200% of the net asset value of Bora Pharmaceuticals USA Inc.
(2) The ceiling on total loans granted by TWi Pharmaceuticals USA Inc. to all parties shall not exceed 200% of the net asset value of TWi Pharmaceuticals USA Inc.

Note 4: Circumstances for the financing provided to others:
(1) Business transaction is "1".
(2) Short-term financing is "2".

Note 5: Where the purpose of the loan is for business transaction (Type "1") the transaction amount represent the accumulated business transactions between the lender and the counter party during the past 12 months.

Note 6: Where the purpose for the loan is short-term financing (Type "2"): Shall specify the reasons for the borrowing and the usage of the funds, such as repayment of loans, acquisition of equipment, working capital, etc.

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
(Amounts are expressed in Thousands of New Taiwan Dollars, unless Otherwise Specified)

Table 3

Endorsement/Guarantee provided to others

No. (Note 1)	Endorser/ Guarantor	Guaranteed party		Limits on endorsement/ guarantee to each guaranteed party (Note3)	Maximum balance for the period	Ending balance	Actual amount drawn down	Amount of endorsement / guarantee secured by collateral	Ratio of accumulated endorsement/ guarantee amount to net equity of the endorser/ guarantor company	Ceiling on total endorsement/ guarantee provided (Note 4)	Guarantee provided by Parent company	Guarantee provided by a subsidiary	Guarantee provided to subsidiaries in Mainland China
		Company name	Relationship (Note 2)										
0	Bora Pharmaceuticals Co., Ltd.	Upsher-Smith Laboratories, LLC	2	$59,982,205	$2,324,350	$2,051,000	$-	$-	17.10%	$59,982,205	Y	N	N
0	Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceuticals Inc.	2	$59,982,205	$598,100	$586,000	$-	$-	4.88%	$59,982,205	Y	N	N
0	Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceuticals Injectables Inc.	2	$59,982,205	$1,345,725	$1,318,500	$879,000	$-	10.99%	$59,982,205	Y	N	N
0	Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Services Inc.	2	$59,982,205	$2,779,200	$2,571,600	$2,571,600	$-	21.44%	$59,982,205	Y	N	N
1	Bora Pharmaceutical Laboratories Inc.	Bora Pharmaceuticals Ophthalmic Inc.	4	$25,756,287	$260,000	$260,000	$260,000	$-	10.09%	$25,756,287	N	N	N

Note 1: The Company and its subsidiaries are coded as follows:

(1) Parent Company is "0".

(2) The subsidiaries are numbered in order from "1".

Note 2: The nature of relationship between endorser/guarantor and guaranteed party is as follows:

(1) Having business relationship.

(2) A company in which the Company holds directly or its subsidiaries hold indirectly, 50% or more of the voting shares.

(3) A company which holds directly or its subsidiaries hold indirectly, 50% or more of the voting shares of the Company.

(4) A company in which the Company holds directly or its subsidiaries hold indirectly, 90% or more of the voting shares.

(5) A company that fulfills its contractual obligations by providing mutual endorsements/guarantees for another company in the same industry or for joint builders for purposes of undertaking a construction project.

(6) A company that all capital contributing shareholders make endorsements/ guarantees for their jointly invested company in proportion to their shareholding percentages.

(7) A company in the same industry provide among themselves joint and several security for a performance guarantee of a sales contract for pre-construction homes pursuant to the Consumer Protection Act for each other,

Note 3: Limit of guarantee/endorsement amount for each receiving party of Bora Pharmaceuticals Co., Ltd. is 5 times of its net worth.
Limit of guarantee/endorsement amount for each receiving party of Bora Pharmaceuticals Laboratories Inc. is 10 times of its net worth.

Note 4: Ceiling on total guarantee/ endorsement amount of Bora Pharmaceuticals Co., Ltd. is 5 times of its net worth.
Ceiling on total guarantee/ endorsement amount of Bora Pharmaceuticals Laboratories Inc. is 10 times of its net worth.

Table 4

Significant marketable securities held as at the end of the reporting period. (Excluding subsidiaries, associates and joint ventures)

Holding Company	Type and name of securities (Note 1)	Relationship (Note 2)	Financial statement account	As of June 30, 2025				Note (Note 4)
				Shares/Units (thousand)	Carrying amount (Note 3)	Percentage of ownership	Fair value	
Upsher-Smith Laboratories, LLC	Non-listed stock－ APPCO Pharma LLC	-	Financial assets measured at fair value through other comprehensive income, non-current	2,791,791.79	$145,861	6.89%	$145,861	No pledged or collateral

Note 1：Securities in the table refer to stocks, bonds, beneficiary certificates and other related derivative securities specified in IFRS9 "*Financial Instrument*"

Note 2：No disclosure is required in this section if the issuer of the securities does not constitute a related party.

Note 3：For items measured at fair value, the carrying amount shall be presented as the amount adjusted for fair value re-measurement. For items not measured at fair value, the carrying amount shall be presented at original acquisition cost or amortized cost, net of accumulated impairment losses.

Note 4：For listed securities subject to usage restrictions due to being provided as collateral, pledged for borrowings, or otherwise restricted by contractual arrangements, the number of shares and amounts pledged or used as collateral, as well as the nature of the restrictions, shall be disclosed in this column

Note 5：The table presents securities identified by the Company for disclosure based on the principle of materiality.

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
(Amounts are expressed in Thousands of New Taiwan Dollars, unless Otherwise Specified)

Table 5

Total purchases from or sales to related parties exceeding the lower of NT$100 million or 20 percent of the capital stock as at the end of the reporting period.

Related party	Counterparty	Relationship	Intercompany transactions				Details of non-arm's length transaction		Notes and accounts receivable (payable)		Note
			Purchases (Sales)	Amount	Percentage of total consolidated purchase (sales)	Terms	Unit price	Terms	Carrying amount	Percentage of total consolidated receivables (payable)	
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Laboratories Inc.	Subsidiary	Sales	$130,228	23.93%	60 days from the date of invoice	Unit price and terms were not significantly different from transactions with third parties		Accounts receivable $83,315	31.82%	
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Services Inc.	Subsidiary	Sales	$151,539	27.85%	60 days from the date of invoice	Unit price and terms were not significantly different from transactions with third parties		Accounts receivable $83,834	32.02%	-
Bora Pharmaceutical Laboratories Inc.	TWi Pharmaceuticals, Inc.	Subsidiary	Sales	$508,141	51.10%	60 days from the date of invoice	Unit price and terms were not significantly different from transactions with third parties		Accounts receivable $246,528	82.24%	-
TWi Pharmaceuticals, Inc.	Upsher-Smith Laboratories, LLC	Subsidiary	Sales	$1,642,725	95.69%	180 days from the date of invoice	Unit price and terms were not significantly different from transactions with third parties		Accounts receivable $1,506,093	98.97%	-
Sunway Biotech Co., Ltd.	3T TECHNOLOGY Co., Ltd.	Substantive related Party	Sales	$109,926	81.45%	Net 60 days	Unit price and terms were not significantly different from transactions with third parties		Accounts receivable $44,374	90.56%	

(Amounts are expressed in Thousands of New Taiwan Dollars, unless Otherwise Specified)

Table 6

Receivables from related parties with amounts exceeding the lower of NT$100 million or 20 percent of capital stock as at the end of the reporting period.

Company Name	Counterparty	Relationship	Ending balance of receivables from related party	Turnover Rate	Overdue		Amount received in subsequent period	Allowance for doubtful debts	Note
					Amount	Action			
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Laboratories Inc.	Subsidiary	Other receivables $311,022	Note 1	Note 1	Note 1	$-	Note 1	–
Bora Pharmaceutical Laboratories Inc.	TWi Pharmaceuticals, Inc.	Subsidiary	Accounts receivable $246,528	6.35	$-	–	$177,734	$-	–
TWi Pharmaceuticals, Inc.	Upsher-Smith Laboratories, LLC	Subsidiary	Accounts receivable $1,506,093	4.36	$-	–	$522,220	$-	–
TWi Pharmaceuticals USA Inc.	Upsher-Smith Laboratories, LLC	Subsidiary	Accounts receivable $970,597	0.02	$950,828	Collected in subsequent reporting period	$-	$-	–
TWi Pharmaceuticals USA Inc.	Upsher-Smith Laboratories, LLC.	Subsidiary	Other receivables $509,052	Note 1	Note 1	Note 1	$-	Note 1	–
Bora Pharmaceuticals USA Inc.	Upsher-Smith Laboratories, LLC.	Subsidiary	Other receivables $2,057,329	Note 1	Note 1	Note 1	$-	Note 1	–
Upsher-Smith Laboratories, LLC.	Pyros Pharmaceuticals Inc.	Subsidiary	Other Receivables $186,075	Note 1	Note 1	Note 1	$-	Note 1	–

Note1: Other receivable of subsidiary, not applicable.

(Amounts are expressed in Thousands of New Taiwan Dollars, unless Otherwise Specified)

Table 7

Information on investees

Investor	Investee company	Location	Main businesses	Initial investment amount		Balance as of June 30, 2025			Net income (loss) of investee	Investment income (loss) recognized	Note
				Ending balance	Beginning balance	Shares	Percentage of ownership	Carrying amount			
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Laboratories Inc.	Miaoli County, Taiwan	Pharmaceutical contract development and manufacturing	$1,435,904	$1,156,810	192,909,368	100%	$2,486,742	$238,194	$229,932	(Note 1)
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceuticals USA Inc.	State of Delaware, USA	Pharmaceutical wholesale	USD 384,631	USD 384,631	500,000	100%	$12,003,785	$(1,353,889)	$(1,302,716)	(Note 1)
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical Services Inc.	Province of Ontario, Canada	Pharmaceutical contract development and manufacturing	CAD 10,000	CAD 10,000	100,000,000	50%	$1,509,634	$171,862	$85,931	-
Bora Pharmaceuticals Co., Ltd.	Bora Management Consulting Co., Ltd.	Taipei City, Taiwan	Management and consulting	$1,000	$1,000	100,000	100%	$1,891	$586	$586	-
Bora Pharmaceuticals Co., Ltd.	Bora Biologics Co., Ltd.	Hsinchu City, Taiwan	Biotechnical services, research and development services and pharmaceutical manufacturing	$-	$2,287,793	-	-%	$-	$(18,359)	$(18,017)	-
Bora Pharmaceuticals Co., Ltd.	Bora Pharmaceutical and Consumer Health Inc.	Taipei City, Taiwan	Biotechnical research and management and consulting	$400	$400	40,000	100%	$37	$(134)	$(134)	-
Bora Pharmaceuticals Co., Ltd.	TWi Pharmaceuticals, Inc.	Taipei City, Taiwan	Pharmaceutical manufacturing and wholesale	$5,397,322	$5,676,416	56,400,000	100%	$5,302,123	$727,712	$1,036,171	(Note 1) (Note 2)
Bora Pharmaceuticals Co., Ltd.	Sunway Biotech Co., Ltd.	Taipei City, Taiwan	Healthcare product wholesale and retail	$1,138,633	$1,138,633	21,615,098	35.81%	$1,154,290	$44,076	$15,775	-

BORA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
(Amounts are expressed in Thousands of New Taiwan Dollars, unless Otherwise Specified)

Investor	Investee company	Location	Main businesses	Initial investment amount		Balance as of June 30, 2025			Net income (loss) of investee	Investment income (loss) recognized	Note
				Ending balance	Beginning balance	Shares	Percentage of ownership	Carrying amount			
Bora Pharmaceuticals Co., Ltd.	Tanvex Biopharma, Inc.	Cayman Islands	Research and development of biosimilar products, biological production procedures and contract development and manufacturing of biological medicine	$4,980,484	$-	72,707,800	30.46%	$4,668,555	$(806,123)	$(222,199)	-
Bora Pharmaceutical Laboratories Inc.	Bora Pharmaceutical Services Inc.	Province of Ontario, Canada	Pharmaceutical contract development and manufacturing	CAD 10,000	CAD 10,000	100,000,000	50%	$1,522,445	$171,862	$85,931	-
Bora Pharmaceutical Laboratories Inc.	Bora Pharmaceuticals Ophthalmic Inc.	Taipei City, Taiwan	Pharmaceutical contract development and manufacturing	$269,612	$260,126	75,000,000	100%	$2,294	$(89,609)	$(89,609)	-
TWi Pharmaceuticals, Inc.	TWi Pharmaceuticals USA ,Inc.	State of New Jersey, USA	Pharmaceutical wholesale	USD 7,600	USD 7,600	38	100%	$1,124,630	$380,192	$380,192	-
Sunway Biotech Co., Ltd.	Sunway Group Holding Limited	Republic of Seychelles	Investment holding	USD 637	USD 637	1,000,000	100%	$419	$(1,384)	$(1,384)	-
Sunway Biotech Co., Ltd.	Chen Run Marketing Co., Ltd.	Taipei City, Taiwan	Healthcare product wholesale	$2,550	$2,550	255,000	51%	$2,721	$23	$12	-
Sunway Biotech Co., Ltd.	Bora Health Inc.	Taipei City, Taiwan	Pharmaceutical wholesale and healthcare product wholesale	$2,141,932	$2,141,932	22,618,880	100%	$353,476	$46,084	$46,084	-
Sunway Biotech Co., Ltd.	GTSW BIOTECH SDN. BHD.	Malaysia	Healthcare product wholesale	MYR 200	MYR 200	200,000	40%	$1,384	$536	$213	-
Sunway Group Holding Limited	Sunway Investment(H.K.) Limited	Hong Kong	Investment holding	USD 623	USD 623	3,500,000	100%	$1,974	$(1,385)	$(1,385)	-
Bora Health Inc.	Union Chemical & Pharmaceutical Co., Ltd.	Taipei City, Taiwan	Pharmaceutical manufacturing and wholesale	$31,557	$31,557	1,500,000	100%	$30,907	$(99)	$(99)	-

(Amounts are expressed in Thousands of New Taiwan Dollars, unless Otherwise Specified)

Investor	Investee company	Location	Main businesses	Initial investment amount		Balance as of June 30, 2025			Net income (loss) of investee	Investment income (loss) recognized	Note
				Ending balance	Beginning balance	Shares	Percentage of ownership	Carrying amount			
Bora Pharmaceuticals USA Inc.	Bora Pharmaceuticals Injectables Inc.	State of Delaware, USA	Pharmaceutical manufacturing and wholesale	USD 70,000	USD 70,000	1,000	100%	$2,243,004	$(286,024)	$(286,024)	-
Bora Pharmaceuticals USA Inc.	Bora Pharmaceutical Holdings, LLC.	State of Delaware, USA	Investment holding	USD 246,251	USD 246,251	1,000	100%	$7,270,671	$(1,433,195)	$(1,433,195)	-
Bora Pharmaceutical Holdings, LLC.	Pyros Pharmaceuticals Inc.	State of Delaware, USA	Pharmaceutical wholesale	USD 47,548	USD 47,548	1,000	100%	$1,250,975	$43,756	$17,684	(Note 2)
Bora Pharmaceutical Holdings, LLC.	Upsher-Smith Holdings, LLC.	State of Minniesota, USA	Investment holding	USD 171,809	USD 171,809	230	100%	$4,928,437	$(1,361,140)	$(1,118,422)	(Note 2)
Bora Pharmaceutical Holdings, LLC.	Upsher-Smith America LLC	State of Minniesota, USA	Investment holding	USD 42,953	USD 42,953	1	20%	$1,285,956	$(1,699,077)	$(279,136)	(Note 2)
Upsher-Smith Holdings, LLC.	Upsher-Smith America LLC	State of Minniesota, USA	Investment holding	USD 791,481	USD 791,481	4	80%	$5,681,588	$(1,699,077)	$(1,359,262)	-
Upsher-Smith America LLC	Upsher-Smith Laboratories, LLC	State of Minniesota, USA	Pharmaceutical manufacturing and wholesale	USD 992,546	USD 992,546	5,976,700 Class A units; 116,235,280 Class B units	100%	$6,365,120	$(1,693,022)	$(1,693,022)	-

Note 1: Adjustment and elimination of side stream transactions.

Note 2: The investment income recognized included the depreciation and amortization expenses resulting from the difference between the identifiable assets at fair value and carrying amount of interests in subsidiary as at the acquisition date.

Table 8

Investment in Mainland China

Investee company	Main businesses and products	Total amount of paid-in capital (in thousands)	Method of investment *(Note 1)*	Accumulated outflow of investment from Taiwan as of January 1, 2025 (in thousands)	Investment flows		Accumulated outflow of investment from Taiwan as of June 30, 2025 (in thousands)	Net income (loss) of investee company	% Ownership of direct or indirect investment	Investment income (loss) recognized *(Note 2)*	Carrying amount as of June 30, 2025	Accumulated inward remittance of earnings as of June 30, 2025
					Outflow	Inflow						
Sunway (Dongguan) Biotech Co., Ltd.	Healthcare product wholesale and retail	CNY 4,000	(ii)	CNY 4,000	$-	$-	CNY 4,000	$(1,330)	100%	$(1,330)	$1,491	$7,725

Accumulated outward remittance for investments in Mainland China as of June 30, 2025 (in thousands)	Investment amounts authorized by Investment Commission, MOEA	Upper limit on the amount of investments stipulated by the Investment Commission, MOEA (Note 3)
CNY 4,000	$19,547	$1,934,024

Note 1 : The methods for engaging in investment in Mainland China include the following:

(i) Direct investment in Mainland China

(ii) Indirectly investment in Mainland China through companies registered in a third region (Please specify the name of the company in third region)

(iii) Other methods.

Note 2：The basis of investment income (loss) recognition is from the financial statements reviewed by an R.O.C. accounting firm.

Note 3：The investment in SunWay Biotech Co., LTD. has been approved by the Investment Commission, MOEA with the limit of amount of 60% of its net worth.